<?xml version='1.0' encoding='UTF-8'?>
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="publisher-id">nss</journal-id>
      <journal-title-group>
        <journal-title>Nature and Science of Sleep</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1179-1608</issn>
      <publisher>
        <publisher-name>Dove</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">37180094</article-id>
      <article-id pub-id-type="pmc">10167974</article-id>
      <article-id pub-id-type="publisher-id">266071</article-id>
      <article-id pub-id-type="doi">10.2147/NSS.S266071</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Considering REM Sleep Behavior Disorder in the Management of Parkinson’s Disease</article-title>
        <alt-title alt-title-type="running-authors">Figorilli et al</alt-title>
        <alt-title alt-title-type="running-title">Figorilli et al</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1638-1384</contrib-id>
          <name>
            <surname>Figorilli</surname>
            <given-names>Michela</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meloni</surname>
            <given-names>Mario</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5659-662X</contrib-id>
          <name>
            <surname>Lanza</surname>
            <given-names>Giuseppe</given-names>
          </name>
          <xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref>
          <xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Casaglia</surname>
            <given-names>Elisa</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5116-5073</contrib-id>
          <name>
            <surname>Lecca</surname>
            <given-names>Rosamaria</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7549-7838</contrib-id>
          <name>
            <surname>Saibene</surname>
            <given-names>Francesca Lea</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7680-8722</contrib-id>
          <name>
            <surname>Congiu</surname>
            <given-names>Patrizia</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6837-6608</contrib-id>
          <name>
            <surname>Puligheddu</surname>
            <given-names>Monica</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
          <xref rid="an0001" ref-type="corresp"/>
        </contrib>
        <aff id="aff0001"><label>1</label><institution>Sleep Disorder Research Center, Department of Medical Sciences and Public Health, University of Cagliari</institution>, <addr-line>Cagliari</addr-line>, <country>Italy</country></aff>
        <aff id="aff0002"><label>2</label><institution>IRCCS, Fondazione Don Carlo Gnocchi ONLUS</institution>, <addr-line>Milan</addr-line>, <country>Italy</country></aff>
        <aff id="aff0003"><label>3</label><institution>Department of Surgery and Medical-Surgical Specialties, University of Catania</institution>, <addr-line>Catania</addr-line>, <country>Italy</country></aff>
        <aff id="aff0004"><label>4</label><institution>Clinical Neurophysiology Research Unit, Oasi Research Institute-IRCCS</institution>, <addr-line>Troina</addr-line>, <country>Italy</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="an0001">Correspondence: Monica Puligheddu, <institution>Sleep Disorder Research Center, Department of Medical Sciences and Public Health</institution>, <addr-line>SS 554 Km 4500, 09042 Monserrato CA</addr-line>, <addr-line>Cagliari</addr-line>, <country>Italy</country>, <addr-line>09042</addr-line>, <phone>Tel +07051096001</phone>, Email puligheddu@unica.it</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>05</day>
        <month>5</month>
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2023</year>
      </pub-date>
      <volume>15</volume>
      <fpage>333</fpage>
      <lpage>352</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>11</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2023 Figorilli et al.</copyright-statement>
        <copyright-year>2023</copyright-year>
        <copyright-holder>Figorilli et al.</copyright-holder>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref>
          <license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Abstract</title>
        <p><citation_analysis attribute="positive">Rapid eye movement (REM) sleep behavior disorder (RBD) is the result of the loss of physiological inhibition of muscle tone during REM sleep, characterized by dream-enacting behavior and widely recognized as a prodromal manifestation of alpha-synucleinopathies. Indeed, patients with isolated RBD (iRBD) have an extremely high estimated risk to develop a neurodegenerative disease after a long follow up. Nevertheless, in comparison with PD patients without RBD (PDnoRBD), the occurrence of RBD in the context of PD (PDRBD) seems to identify a unique, more malignant phenotype, characterized by a more severe burden of disease in terms of both motor and non-motor symptoms and increased risk for cognitive decline. However, while some medications (eg, melatonin, clonazepam, etc.) and non-pharmacological options have been found to have some therapeutic benefits on RBD there is no available treatment able to modify the disease course or, at least, slow down the neurodegenerative process underlying phenoconversion. In this scenario, the long prodromal phase may allow an early therapeutic window and, therefore, the identification of multimodal biomarkers of disease onset and progression is becoming increasingly crucial. To date, several clinical (motor, cognitive, olfactory, visual, and autonomic features) neurophysiological, neuroimaging, biological (biofluids or tissue biopsy), and genetic biomarkers have been identified and proposed, also in combination, as possible diagnostic or prognostic markers, along with a potential role for some of them as outcome measures and index of treatment response. In this review, we provide an insight into the present knowledge on both existing and future biomarkers of iRBD and highlight the difference with PDRBD and PDnoRBD, including currently available treatment options.</citation_analysis></p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <title>Keywords</title>
        <kwd>Parkinson’s disease</kwd>
        <kwd>REM sleep behavior disorder</kwd>
        <kwd>synucleinopathy</kwd>
        <kwd>biomarkers</kwd>
        <kwd>neurodegeneration</kwd>
      </kwd-group>
      <counts>
        <fig-count count="1"/>
        <table-count count="3"/>
        <ref-count count="172"/>
        <page-count count="20"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s0001">
      <title>RBD in Neurodegenerative Disease, a Window into Prodromal Parkinson’s Disease</title>
      <p><citation_analysis attribute="neither">REM sleep behavior disorder (RBD) is a parasomnia characterized by dream-enacting behavior and loss of physiological muscle atonia during REM sleep (REM sleep without atonia, RSWA).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0002" ref-type="bibr">2</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Concerning RBD pathophysiology, studies mainly based on animal models seem to indicate the neurodegeneration of SLD glutamatergic and/or medullo-pontin GABA/glycinergic neurons as the cause of RBD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0003" ref-type="bibr">3</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">RBD may be isolated (iRBD) when non associated to other neurological diseases</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0004" ref-type="bibr">4</xref></citation_analysis><citation_analysis attribute="neither"> reaching a prevalence of about 0.5–1% in the general population over 60 years.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0005" ref-type="bibr">5</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither"> RBD is also widely recognized as a prodromal manifestation of alpha-synucleinopathies, it is present when the neurodegeneration progress has already started but cardinal symptoms of the disease have not yet manifested.</citation_analysis></p>
      <p><citation_analysis attribute="neither">In fact, about 90% of patients with iRBD at 15 years of follow-up receive a clinical diagnosis of alpha-synucleinopathy, namely Lewy Body Dementia (DLB) in about 45%, Parkinson’s disease (PD) in 45%, and multiple system atrophy (MSA) in 5%.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0008" ref-type="bibr">8</xref></citation_analysis></p>
      <p><citation_analysis attribute="negative">Additionally, RBD associated with PD (PDRBD) seems to identify a malignant phenotype characterized with a more severe burden of disease in terms of motor and non-motor symptoms, and increased risk for cognitive decline, compared to PD patients without RBD (PDnoRBD).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis></p>
      <p><citation_analysis attribute="negative">Managing of RBD includes pharmacological interventions (Clonazepam, Melatonin), bedroom interventions aimed to mitigate the risk of injuries improving the safety of both the patient and the bed-partner, in order to reduce dream-enacting behaviors, associated nightmares and consequent injuries, and to improve the quality of life. Moreover, in managing RBD it is important to inform the patient about the association between RBD and neurodegenerative disorders and scheduling follow-up neurological examinations in order to early recognize any sign of synucleinopathies.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0002" ref-type="bibr">2</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0008" ref-type="bibr">8</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Up to now, neuroprotective and disease-modifying therapy are not available, in order to arrest or slow down the neurodegenerative process of alphasynucleinopathy. RBD population represents an ideal candidate to neuroprotective or disease-modifying clinical trial. Thus, the identification of multimodal biomarkers, both diagnostic and prognostic, of neurodegeneration is crucial. In this review, we provide an insight into the present knowledge on both existing and future biomarkers of iRBD and highlight the difference with PDRBD and PDnoRBD, including currently available treatment options.</citation_analysis></p>
    </sec>
    <sec id="s0002">
      <title>Parkinson’s Disease Associated with RBD a New Phenotype Within the Spectrum of Alpha-Synucleinopathies</title>
      <p><citation_analysis attribute="positive">Although Parkinson’s disease was initially considered a single entity, soon biological and instrumental evidence reflecting the heterogeneity of possible clinical trajectories, allowed the delineation of phenotypes that not only are guiding the search for the underlying pathological mechanisms of the disease, but can predict its course and which will become increasingly crucial once targeted therapeutic options become available.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0010" ref-type="bibr">10</xref></citation_analysis><citation_analysis attribute="neither"> The concept of RBD heralding synucleinopathies was introduced in 1996,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0011" ref-type="bibr">11</xref></citation_analysis><citation_analysis attribute="neither"> but only in recent decades RBD and non-motor symptoms has been accorded the importance they deserve. Many years have elapsed since Braak postulated his famous hypothesis according to which the key lesions of the pathology begin to develop long before the onset of cardinal somato-motor symptoms of the disease, with an ascending and predictable topographical sequence.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0013" ref-type="bibr">13</xref></citation_analysis><citation_analysis attribute="neither"> The first structures to be affected would be located in this model at the level of the medulla oblongata and pons, which may associate not only, as postulated by the author, with the onset of non-motor symptoms such as hyposmia and autonomic dysfunction, but structures critical for the preservation of physiological atonia during REM sleep.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12</xref></citation_analysis><citation_analysis attribute="neither"> Subsequently, involvement of the substantia nigra and other nuclear grays of the midbrain and forebrain would occur and then end at stages 5–6 with involvement of the neocortex.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0014" ref-type="bibr">14</xref></citation_analysis><citation_analysis attribute="neither"> Regarding pathogenesis of PD, one of the most famous theories is the dual-hit hypothesis: a pathogenic agent spreading in a prion-like manner, leading to the accumulation of misfolded alpha-synuclein aggregates, would have access to the brain through the olfactory bulb and the dorsal motor nucleus of the vagus (DMV).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0016" ref-type="bibr">16</xref></citation_analysis><citation_analysis attribute="positive"> Although a large proportion of studies seem to confirm the validity of Braak’s model in most cases, it is also true that incidental PD may show pathological aggregates in substantia nigra or elsewhere in the brain with no implication of the dorsal motor nucleus of the vagus.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0017" ref-type="bibr">17</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0018" ref-type="bibr">18</xref></citation_analysis><citation_analysis attribute="neither"> These observations implying heterogeneity in the sites of origin from which alphasynucleinopathy progresses actually accord with the recent identification of two phenotypes, in contrast for their different spreading patterns: a brain-first (top-down) where the pathology originates in the central nervous system,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> and a body-first (bottom-up) type in which a-synuclein pathology initially arises in the enteric or peripheral autonomic nervous system.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis><citation_analysis attribute="neither"> Premotor RBD is in this model a key clinical indicator of a body-first phenotype, in fact, the pons is involved before the substantia nigra in a bottom-up model; however, since late top-down involvement cannot be excluded, it is only iRBD that can be used as an early and distinctive biomarker of this phenotype.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0020" ref-type="bibr">20</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0021" ref-type="bibr">21</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, the nigrostriatal dopamine system is widely preserved in many iRBD cases,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis><citation_analysis attribute="neither"> whereas enteric phosphorylated α-synuclein histopathology (PASH) was found more frequent in a RBD subgroup of patients compared to PD patients without RBD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0022" ref-type="bibr">22</xref></citation_analysis><citation_analysis attribute="neither"> However, PDRBD patients also appear to display a more severe cerebral pathological involvement, reflecting a possible broader and heavier diffusion of alpha synucleinopathy in these subjects.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="positive"> To demonstrate the validity of the dichotomous brain first or gut first model, Horsager et al have investigated de novo PD patients with and without RBD through multimodal imaging studies and compared the results with those obtained in iRBD patients.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0020" ref-type="bibr">20</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Pre-motor RBD Parkinson’s disease and iRBD groups showed significantly reduced 11C-colonic donepezil and cardiac MIBG signal, mildly decreased locus coeruleus neuromelanin signal and colonic changes like an augmented colon volume and transit time, providing major support for the body-first disease subtype identification.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0020" ref-type="bibr">20</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0024" ref-type="bibr">24</xref></citation_analysis><citation_analysis attribute="neither"> The alpha-Synuclein Origin site and Connectome (SOC) model, proposed by Borghammer could be considered to some extent an evolution of the Brain-first/Body-first.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0025" ref-type="bibr">25</xref></citation_analysis><citation_analysis attribute="positive"> According to this theory, the anatomical point of origin of alpha-synucleinopathy spread and the density of ipsilateral connections dominating intra-cerebral propagation appear to be a potential explanation for the asymmetric involvement at the hemispheric level in CNS-first patients, whereas in the bottom-up model the differences in neuropathological diffusion in the two hemispheres are more subtle.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0025" ref-type="bibr">25</xref></citation_analysis><citation_analysis attribute="positive"> In addition to the asymmetry in motor symptoms it is also suggested by the author that the greater prevalence and severity in cognitive involvement in body-first patients is due to the fact that at the time of diagnosis of parkinsonism in this subgroup the alpha-synucleinopathy is already widely spread bilaterally in the brainstem and hemispheric regions, and presenting the aforementioned with a much more protracted prodromal phase.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0025" ref-type="bibr">25</xref></citation_analysis><citation_analysis attribute="neither"> Indeed, brain atrophy seems to be already present in de novo PDRBD, which as we have seen appears to be a body-first type hallmark, and there seems to be a stronger correlation between volume reduction of thalamus, hippocampus, and putamen in particular and a severer cognitive impairment.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0026" ref-type="bibr">26</xref></citation_analysis><citation_analysis attribute="neither"> Most early subtyping systems were based on age at onset and tremor versus akinetic-rigid predominance in general, on variables that were selected a priori, whereas, in order to improve the reliability and reproducibility of the identified phenotypes, more recent studies are adopting a hypothesis-free data-driven approach, giving increasing importance to non-motor symptoms such as RBD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0010" ref-type="bibr">10</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0027" ref-type="bibr">27</xref></citation_analysis><citation_analysis attribute="neither"> Regardless, the dominant motor phenotype of tremor has always been found to have a more favorable prognosis than the postural instability and gait disturbance (PIGD) phenotype,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> and, in general, the dominant non-tremor subtypes have always been associated with a wider range of nonmotor symptoms, with early predominance of autonomics and later cognitive impairment as the most common nonmotor issues.</citation_analysis></p>
      <p><citation_analysis attribute="neither">Fereshtehnejad et al, analyzing a comprehensive array of motor and nonmotor features in PD patients were able to identify three clinical subtypes: “mild motor-predominant”, “intermediate” and “diffuse malignant”.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0028" ref-type="bibr">28</xref></citation_analysis><citation_analysis attribute="neither"> Interestingly, the most discriminating features were mild cognitive impairment, orthostatic hypotension, and RBD. Patients with the diffuse malignant subtype presented not only with a severer dopaminergic deficit on SPECT and atrophy in disease-specific brain networks</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0029" ref-type="bibr">29</xref></citation_analysis><citation_analysis attribute="neither"> but also displayed an Alzheimer’s disease-like CSF profile and faster progression of cognitive, motor, and other nonmotor domains.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis></p>
      <p><citation_analysis attribute="negative">Finally, PDRBD may mark a unique, more malignant subtype of alphasynucleinopathy, with different neuropathological and genetic background and independent risk factor profile,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither"> which, however, given the long prodromal phase could ensure the identification of an early therapeutic window once disease-modifying treatments are identified.</citation_analysis></p>
    </sec>
    <sec id="s0003">
      <title>REM Sleep Behavior Disorder and Biomarkers for Phenoconversion Prediction</title>
      <p><citation_analysis attribute="positive">Patients with iRBD have an estimated risk to develop a neurodegenerative disease (such as PD, MSA and LBD) up to 90% after a long follow up: 44.8% after 6 years, and from 67.5%</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither"> to 81% after 10 years.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">This means that diagnosis of RBD offers a unique clue to individuate a cohort of patients that can be eligible for neuroprotective and disease modifying drug trials or therapy in the future.</citation_analysis></p>
      <p><citation_analysis attribute="neither">In order to do so it is crucial to understand which features are associated with phenoconversion and with faster neurodegeneration, consequently during the last years, many longitudinal studies focused on the individuation of potential biomarkers of disease progression.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Ideally, a good biomarker must have a good sensitivity and specificity, must be easily available and be useful both as a marker for progression and also as a marker for therapy response in neuroprotective therapy trials.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">To date, several clinical (motor symptoms, cognition, olfactive symptoms, visive function, autonomic function) neurophysiological, neuroimaging, biological (biofluids or tissue biopsy) and genetic biomarkers have been individuated. They can be classified accordingly to the purpose they serve as diagnostic biomarkers (to confirm diagnosis of alpha-synucleinopathy), prognostic biomarkers, (to predict phenoconversion), monitoring or therapy responsive (to monitor neurodegenerative progression and possible effect of therapies) and combined biomarkers.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive"><xref rid="t0001" ref-type="table">Table 1</xref></citation_analysis><citation_analysis attribute="neither"> summarizes the biomarkers of neurodegeneration in iRBD.</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0001"><label>Table 1</label><caption><p><citation_analysis attribute="neither">Biomarkers of Neurodegeneration in Isolated REM Sleep Behavior Disorder (iRBD)</citation_analysis></p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="7" colspan="1"><bold>Clinical</bold></td><td rowspan="1" colspan="1">Motor function</td><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Early alterations on UPDRSIII scale</citation_analysis></p></list-item><list-item><p><citation_analysis attribute="neither">Early alteration of gait, balance and bradikinesia</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1">Smell</td><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Early presence of Hyposmia and altered smell test</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1">Visual function</td><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Altered color discrimination, stereopsis and retinal thinning at OCT</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="4" colspan="1">Autonomic function</td><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="negative">Decreased Heart rate variability</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Presence of urinary dysfunction</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Presence of sexual dysfunction</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Ortostatic hypotension</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="5" colspan="1"><bold>Biological</bold></td><td rowspan="3" colspan="1">Blood test</td><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Alpha-synuclein in neuronal circulating exosomes,</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Research of neurofilaments in serum</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Circulating micro-RNA</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1">CSF</td><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Elevated misfolded with RT-QuIC</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1">Tissue Biopsy</td><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Presence α-synuclein in colon mucosae, salivary glands and skin</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="5" colspan="1"><bold>Neuroimaging</bold></td><td rowspan="2" colspan="1"><sup>123</sup>I-FP-CIT SPECT</td><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Nigrostriatal dopamine impairment</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Decreased dopamine uptake in striatum and putamen</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1">Glucose metabolism SPECT and PET</td><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Abnormal/increased metabolic activity in hyppocampus</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1">Structural MRI</td><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Deep gray matter and cortical gray matter degeneration</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1">f-MRI</td><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">Altered connectivity in basal ganglia, in cortico-striatal and cortico-cortical networks</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="3" colspan="1"><bold>Genetics</bold></td><td rowspan="3" colspan="1"/><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">GBA variants</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">SNCA</citation_analysis></p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><citation_analysis attribute="neither">TMEM175</citation_analysis></p></list-item></list></td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><citation_analysis attribute="positive"><bold>Abbreviations</bold></citation_analysis><citation_analysis attribute="neither">: UPDRS, Unified Parkinson’s Disease Rating Scale; OCT, Optical coherence tomography; RT-QuIC, real-time quaking-induced conversion.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis></p>
      <sec id="s0003-s2001">
        <title>Clinical Biomarkers</title>
        <p><citation_analysis attribute="positive">Motor function can be altered in iRBD patients, in a large multicenter study, Unified Parkinson’s disease Rating Scale (UPDRS) and quantitative motor test demonstrated to be powerful predictive factor of phenoconversion with an HR of 3.16 (95% CI 1.86–5.37),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither"> moreover, UPDRS-III motor score may be altered starting from 6.5 years before diagnosis.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0035" ref-type="bibr">35</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">More recently assessment of motor function with wearable devices or computer detection algorithms was used in several studies, allowing an objective evaluation of gait,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0036" ref-type="bibr">36</xref></citation_analysis><citation_analysis attribute="neither"> balance,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0037" ref-type="bibr">37</xref></citation_analysis><citation_analysis attribute="neither"> eye movements,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0038" ref-type="bibr">38</xref></citation_analysis><citation_analysis attribute="neither"> and bradykinesia.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">All these cross sectional studies showed promising results in the detection of alterations that can be used as biomarkers for phenoconversion, with sensitivity and specificity up to 80%;</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither"> these systems are relatively easy to use and low cost and can be used at patient’s home,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0036" ref-type="bibr">36</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0037" ref-type="bibr">37</xref></citation_analysis><citation_analysis attribute="neither"> however further studies on larger population are needed for the validation of their use in clinical practice.</citation_analysis></p>
        <p><citation_analysis attribute="neither">Hyposmia is recognized together with RBD a prodromal symptom of PD,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0040" ref-type="bibr">40</xref></citation_analysis><citation_analysis attribute="neither"> with 67% of patients with RBD presenting with this symptom.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis></p>
        <p><citation_analysis attribute="negative">The presence of hyposmia or anosmia is considered a low term risk factor for the development of alpha-synucleinopathy in iRBD patients,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0041" ref-type="bibr">41</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0042" ref-type="bibr">42</xref></citation_analysis><citation_analysis attribute="positive"> but smell test did not show any changes in time, therefore this symptom should be used as a prognostic marker at the moment of RBD diagnosis, but not as a monitoring biomarker in clinical intervention trials.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0041" ref-type="bibr">41</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">Visual impairment, another common finding in alpha-synucleinopathies, can also be present in patients with iRBD in different forms, ranging from altered color discrimination,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0043" ref-type="bibr">43</xref></citation_analysis><citation_analysis attribute="neither"> stereopsis</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0044" ref-type="bibr">44</xref></citation_analysis><citation_analysis attribute="neither"> and retinal thinning,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0045" ref-type="bibr">45</xref></citation_analysis><citation_analysis attribute="neither"> suggesting that color vision test and optical coherence tomography (OCT) may be used as potential diagnostic and prognostic markers.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">Finally, another clinical feature that can be used as biomarker for phenoconversion is autonomic dysfunction, symptoms such as orthostatic hypotension, sexual and urinary dysfunction and constipation</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0046" ref-type="bibr">46</xref></citation_analysis><citation_analysis attribute="neither"> are present in up to 94% patients with RBD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0047" ref-type="bibr">47</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, autonomic dysfunction is one of the cardinal nonmotor symptoms of PD and in patients with iRBD can appear several years before the diagnosis of alpha-synucleinopathy.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0047" ref-type="bibr">47</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">Different studies reported a reduced heart rate variability (HRV) in iRBD patients,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0048" ref-type="bibr">48</xref></citation_analysis><citation_analysis attribute="neither"> which also correlated with quantified tonic RSWA,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0049" ref-type="bibr">49</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0050" ref-type="bibr">50</xref></citation_analysis><citation_analysis attribute="neither"> however there is not a clear difference between patients who converted to a neurodegenerative disorder and those who did not.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0048" ref-type="bibr">48</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">Even though longitudinal studies are still needed in order to have a standardization and clear cut-off values, performing a clinical assessment of motor, autonomic, olfactive and visual function is easy and low cost and is fundamental during baseline and follow-up visits of iRBD patients to predict and detect early signs of alfa-synucleinopathies</citation_analysis></p>
      </sec>
      <sec id="s0003-s2002">
        <title>Neuroimaging</title>
        <p><citation_analysis attribute="neither">The use of neuroimaging in PD has greatly developed in the last decade, mostly with the purpose to detect early impairment of nigrostriatal dopaminergic circuit and dopamine transport alteration in the basal ganglia circuit with the use of PET and SPECT imaging.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">The most studied is </citation_analysis><citation_analysis attribute="positive"><sup>123</sup></citation_analysis><citation_analysis attribute="neither">I-FP-CIT SPECT for the assessment of dopamine transporter: many patients with iRBD have nigrostriatal dopamine impairment:</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0051" ref-type="bibr">51</xref></citation_analysis><citation_analysis attribute="positive"> decreased dopamine uptake in striatum and putamen demonstrated to predict phenoconversion with strong sensitivity and specificity,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52–54</xref></citation_analysis><citation_analysis attribute="neither"> especially when combined to clinical biomarkers such as autonomic impairment.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0055" ref-type="bibr">55</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">The use of </citation_analysis><citation_analysis attribute="positive"><sup>123</sup></citation_analysis><citation_analysis attribute="neither">I-FP-CIT SPECT is a powerful biomarker for phenoconversion and can also serve as a prognostic marker for neuroprotective therapy trials.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0056" ref-type="bibr">56</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">Other PET and SPECT techniques for the study of glucose metabolism and perfusion demonstrated abnormal metabolic activity, especially in hippocampus,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0057" ref-type="bibr">57</xref></citation_analysis><citation_analysis attribute="neither"> in RBD patients who converted to PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0058" ref-type="bibr">58</xref></citation_analysis><citation_analysis attribute="positive"> Seriated follow up imaging demonstrated an increase in time of PD related pattern expression, making it a potential marker for prediction of short term phenoconversion.</citation_analysis></p>
        <p><citation_analysis attribute="positive">Although these promising results, SPECT and PET are not available in all centers and expose the patient to radiation, therefore MRI has been considered as an alternative: structural studies demonstrated a reduction in deep gray matter and cortical gray matter degeneration in patients with RBD, along with changes in white matter typically found in neurodegenerative disorders.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0059" ref-type="bibr">59</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">Functional MRI studies (f-MRI) showed altered connectivity not only within basal ganglia, but also in cortico-striatal and cortico-cortical networks.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0060" ref-type="bibr">60</xref></citation_analysis></p>
      </sec>
      <sec id="s0003-s2003">
        <title>Biological</title>
        <p><citation_analysis attribute="positive">A more feasible and low cost alternative to imaging studies, may be biomarkers obtained from blood; however, research of alpha-synuclein in neuronal circulating exosomes, research of neurofilaments in serum and circulating micro RNA have only shown encouraging results and heir validity as biomarker is yet to be confirmed.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">A novel approach is the detection of alpha synuclein in neuronal extracellular vesicles, which are vesicles released from CNS cells that can transport and spread proteins, including pathological ones, they pass the blood brain barrier and spread the neuropathological proteins.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0061" ref-type="bibr">61</xref></citation_analysis><citation_analysis attribute="neither"> Patological soluble alpha-synuclein in neuronal extracellular vesicles is significantly higher in patients with PD compared to controls, this novel approach is promising and will need further validation.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0062" ref-type="bibr">62</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">In many patients with iRBD abnormal deposits of α-synuclein have been documented in olfactory mucosa,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0063" ref-type="bibr">63</xref></citation_analysis><citation_analysis attribute="neither"> in peripheral organs (skin, colon and salivary glands)</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0064" ref-type="bibr">64</xref></citation_analysis><citation_analysis attribute="neither"> and misfolded α-synuclein has also been detected in the cerebral spinal fluid (CSF).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0065" ref-type="bibr">65</xref></citation_analysis></p>
        <p><citation_analysis attribute="negative">Recently, detection in CSF of pathologically misfolded α-synuclein with the use of Real-time quaking-induced conversion (RT-QuIC) showed very promising results with a sensitivity and specificity of 90% in patients with iRBD, and its positivity was associated with an increased risk of phenoconversion.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0065" ref-type="bibr">65</xref></citation_analysis><citation_analysis attribute="neither"> The same technique applied to swabs from olfactory mucosa, less invasive than lumbar puncture, showed a 90% specificity but lower sensitivity.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0063" ref-type="bibr">63</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">Quantification of α-synuclein in tissue research has emerged as an interesting biomarker, also providing information on its deposition spread over time. Studies on samples from colon mucosae, salivary glands and skin using antibodies targeting phosphorylated α-syn showed good sensitivity and specificity in iRBD patients, with skin biopsy coming up as the most promising technique.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0064" ref-type="bibr">64</xref></citation_analysis></p>
      </sec>
      <sec id="s0003-s2004">
        <title>Genetics</title>
        <p><citation_analysis attribute="neither">Several gene mutation related to Parkinson disease and other synucleinopathies have been discovered during the last 40 years, detection of gene mutations associated to PD in patients with RBD can represent a biomarker for phenoconversion prediction.</citation_analysis></p>
        <p><citation_analysis attribute="neither">GBA, the gene encoding for Glucocerebrosidase, is more frequently mutated in patients with PDRBD than in patient with PDnoRBD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0066" ref-type="bibr">66</xref></citation_analysis><citation_analysis attribute="negative"> Frequency of GBA mutation in iRBD was higher than in control population and associated with a risk of conversion to PD and DLB,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0067" ref-type="bibr">67</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0068" ref-type="bibr">68</xref></citation_analysis><citation_analysis attribute="neither"> and was also more frequent in patients with iRBD compared to PD patients with unknown RBD status.</citation_analysis></p>
        <p><citation_analysis attribute="neither">Other genes potentially involved in neurodegeneration progress are SNCA variants</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0069" ref-type="bibr">69</xref></citation_analysis><citation_analysis attribute="neither"> and TMEM175.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0070" ref-type="bibr">70</xref></citation_analysis></p>
      </sec>
    </sec>
    <sec id="s0004">
      <title>RBD as a Cognitive Decline Risk Factor</title>
      <p><citation_analysis attribute="positive">Several studies have shown impairment in different cognitive domains, including memory, attention, executive functions and visuospatial abilities, in RBD patients, both idiopathic and associated with PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0071" ref-type="bibr">71–73</xref></citation_analysis><citation_analysis attribute="neither"> Likewise, presence of mild cognitive impairment (MCI) and reduced cognitive performances seem to predict the phenoconversion of iRBD patients into a neurodegenerative disease.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0071" ref-type="bibr">71</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, MCI and/or impaired attention and executive functions might predict conversion to dementia prior to parkinsonism in iRBD patients.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0074" ref-type="bibr">74</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Up to 50% of iRBD and 73% of PDRBD show MCI, in particular, RBD in PD was associated with a more impaired cognitive performances compared to PDnoRBD patients and to healthy controls (HC).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0073" ref-type="bibr">73</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0075" ref-type="bibr">75</xref></citation_analysis><citation_analysis attribute="neither"> RSWA, the neurophysiological hallmark of RBD, have been correlated with reduced cognitive performances, namely attention, executive functions, episodic verbal and learning memory, verbal fluency and visuospatial abilities, in PDRBD compared to PDnoRBD and HC.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0073" ref-type="bibr">73</xref></citation_analysis><citation_analysis attribute="positive"> Furthermore, higher RSWA can discriminate probable synucleinopathy from probable non-synucleinopathy in older adults with cognitive impairment, including in those with no clinical symptoms of dream enactment.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0076" ref-type="bibr">76</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">MRI cortical thinning in the left anterior temporal cortex has been correlated with cognitive impairment in iRBD patients with MCI, and more precisely, reduced attention and executive function has been associated with thinning of the frontal cortex, reduced verbal learning with thinning in left temporal cortex and visuospatial abilities has been correlated with thinning of the fronto-temporal cortex in iRBD patients.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0077" ref-type="bibr">77</xref></citation_analysis><citation_analysis attribute="positive"> Moreover, atrophy in the basal ganglia, thalamus, amygdala and frontotemporal grey and white matter might predict cognitive decline in both iRBD and PD, by means of MRI using partial least squares.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0078" ref-type="bibr">78</xref></citation_analysis><citation_analysis attribute="positive"> More recently, iRBD patients with MCI have shown a widespread pattern of local alteration and volume atrophy in both cortical and subcortical regions compared to iRBD without MCI and controls.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0079" ref-type="bibr">79</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">RBD is an heterogeneous clinical and neurophysiological entity, up to 50% of iRBD patients will develop DLB and the remainder will convert to a parkinsonism (PD&gt;MSA).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0080" ref-type="bibr">80</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0081" ref-type="bibr">81</xref></citation_analysis><citation_analysis attribute="negative"> Thus, it is crucial to phenotype iRBD patients in dementia-first and parkinsonism-first converters. Presence of MCI, both amnestic and non-amnestic, in iRBD seems to be a key risk factor to dementia-first phenoconversion.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0082" ref-type="bibr">82</xref></citation_analysis><citation_analysis attribute="positive"> Recently, cognitive impairment has been considered as a prodromal marker of alphasynucleinopathy and has been incorporated in the last updated research criteria for prodromal PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0083" ref-type="bibr">83</xref></citation_analysis><citation_analysis attribute="neither"> Different evidences suggest that RBD together with hyposmia and reduced dopamine transporter binding, prodromal signs of PD, might be associated with worse cognitive performances compared with subjects without any or with only one of these prodromal signs.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0075" ref-type="bibr">75</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0084" ref-type="bibr">84</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, PD associated with RBD has been identified as a diffuse-malignant phenotype characterized by a heavier burden of disease in terms of motor and non-motor symptoms, namely cognitive decline and dysautonomia and a more rapid progression compared to the other two PD phenotype, “mild motor predominant” and “intermediate”.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0029" ref-type="bibr">29</xref></citation_analysis><citation_analysis attribute="positive"> Also, the diffuse-malignant PDRBD phenotype has shown more atrophy in substantia nigra-connected areas, more dopaminergic deficit on SPECT and reduced amyloid-b in CSF compared to the others.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="positive"> Thus, RBD might be associated with a more widespread neurodegenerative process involving cortical-subcortical-mesolimbic networks. Further longitudinal studies are needed in order to intercept iRBD patients at risk to develop cognitive decline, a specific population that might be included in future clinical trials for disease-modifying therapy for alpha-synucleinopathies and clinical trials for therapies targeting cognition in PD.</citation_analysis></p>
    </sec>
    <sec id="s0005">
      <title>Neurophysiological Biomarkers of Neurodegeneration in RBD</title>
      <sec id="s0005-s2001">
        <title>Electroencephalography (EEG)</title>
        <p><citation_analysis attribute="positive">iRBD subjects showed some EEG changes which have been demonstrated also in those with PD and DLB, including diffuse slowing in wakefulness EEG recordings, though this was particularly evident on posterior brain regions.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0085" ref-type="bibr">85</xref></citation_analysis><citation_analysis attribute="negative"> Notably, the cortical slowdown was related to cognitive impairment, thus hypothesizing a correlation between electrophysiological and neuropsychological features. Moreover, higher absolute delta and theta power from all cortical areas allowed to identify those patients at greater risk of short-term conversion into synucleinopathies.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0086" ref-type="bibr">86</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">Both macro- and microstructure sleep alterations derived from EEG have been suggested as electrophysiological indexes, although prospective studies have not been performed yet. Only an earlier study found that quantification of RSWA, in particular the baseline high tonic chin EMG activity, may detect a greater risk of progression into PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0085" ref-type="bibr">85</xref></citation_analysis><citation_analysis attribute="neither"> A more recent study with high-density EEG showed that, unlike RBD patients, good sleepers displayed a decreased beta power during phasic with respect to tonic REM sleep. Furthermore, RBD individuals showed a lower SWA decline from early to late non-REM sleep, as well as decreased overnight modifications in the slow-wave amplitude distribution.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0087" ref-type="bibr">87</xref></citation_analysis><citation_analysis attribute="positive"> As such, because of the lack of suppression of the beta rhythms during phasic REM sleep, RBD subjects would show an increase in cortical arousal, thus likely favoring the presence of REM behavioral episodes.</citation_analysis></p>
        <p><citation_analysis attribute="neither">A further report demonstrated, during REM sleep, the increase of instability of EEG microstructure in de novo iRBD subjects,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0088" ref-type="bibr">88</xref></citation_analysis><citation_analysis attribute="neither"> with power EEG spectrum frequency lower than 15 Hz indicating a reduced REM-related decrease than in controls and an increased beta band, which might correlate with persistent muscular activation. Of note, clonazepam partially recovered the power of frequencies lower than 15 Hz; also, the increased EEG power instability was remarkably reduced by this treatment.</citation_analysis></p>
        <p><citation_analysis attribute="neither">Based on the same rationale, clonazepam might be effective also for PDRBD, as clinically highlighted by recent randomized double-blind clinical trials and systematic reviews/meta-analysis.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0089" ref-type="bibr">89–93</xref></citation_analysis><citation_analysis attribute="positive"> Considering these objective findings, indeed, clonazepam may act by reducing the negative effects from the supratentorial network rather than acting directly on the infratentorial pathology of RBD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0088" ref-type="bibr">88</xref></citation_analysis><citation_analysis attribute="positive"> However, its efficacy at EEG level has been demonstrated only in a mouse model of RBD, and not yet in patients with PDRBD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0094" ref-type="bibr">94</xref></citation_analysis><citation_analysis attribute="positive"> Therefore, we recommend continuing the studies to reveal whether there is not only a subjective but also an objective improvement in these patients as well.</citation_analysis></p>
        <p><citation_analysis attribute="neither">The investigation on the cyclic alternating pattern (CAP) has been conducted as well.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0095" ref-type="bibr">95</xref></citation_analysis><citation_analysis attribute="neither"> A previous study observed an increase of slow EEG transients (A1 CAP subtypes) and a decrease of fast EEG events (A2 and A3 CAP subtypes) in drug-naïve iRBD individuals.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0089" ref-type="bibr">89</xref></citation_analysis><citation_analysis attribute="neither"> In this report, long-term intake of clonazepam improved the stability of non-REM sleep and EEG transients duration. Different results come from another study, ie, a global increased CAP, particularly due to the A2 and A3 subtypes; conversely, the A1 subtype decreased in RBD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0096" ref-type="bibr">96</xref></citation_analysis><citation_analysis attribute="neither"> Lastly, another investigation in iRBD showed a decrease of global CAP measures, mostly due to a decreased A1 CAP subtype.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0097" ref-type="bibr">97</xref></citation_analysis><citation_analysis attribute="neither"> Taken together, the impact of non-REM sleep instability on RBD is still inconclusive.</citation_analysis></p>
        <p><citation_analysis attribute="neither">In addition, the density of sleep spindles was found to be altered in RBD patients, with a decreased fast but increased slow spindles, that was viewed as a possible marker predictive of a neurodegenerative disorder.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0098" ref-type="bibr">98</xref></citation_analysis><citation_analysis attribute="neither"> A further report revealed a diffuse decreased spindle density both in iRBD patients and in those with PDRBD, thus proposing it as a supportive diagnostic tool.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0099" ref-type="bibr">99</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">Recently, it should be mentioned an advanced EEG-based study in which the analysis method reported theta-band bursts and decreased alpha-band burst during the eye-closed wakefulness, which may predict the progression into DLB or PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0100" ref-type="bibr">100</xref></citation_analysis><citation_analysis attribute="positive"> Very recently, EEG power analyses showed a significant lower alpha and higher delta power in iRBD phenoconverters during the phasic REM state, which was more evident over the occipital and central cortical areas, with respect to those patients who remained disease-free.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0101" ref-type="bibr">101</xref></citation_analysis><citation_analysis attribute="negative"> Significant higher slow-to-fast ratio during the phasic state was noted more diffusely in iRBD converters than in non-converters. The further analysis of slowing ratio during phasic REM sleep from occipital regions resulted in a remarkable area under the curve, whereas the subjective RBD severity did not have any predictive value. The authors concluded that EEG slowing (especially when generalized during the phasic period), rather than subjective RBD severity, may be promising in predicting phenoconversion.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0101" ref-type="bibr">101</xref></citation_analysis></p>
      </sec>
      <sec id="s0005-s2002">
        <title>Motor Evoked Potentials (MEPs)</title>
        <p><citation_analysis attribute="neither">MEPs to transcranial magnetic stimulation (TMS) have been tested in sleep disorders to evaluate and non-invasively modulate cortical excitation, neuroplasticity, and brain connectivity.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0102" ref-type="bibr">102–105</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">The first TMS study in RBD</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0106" ref-type="bibr">106</xref></citation_analysis><citation_analysis attribute="neither"> found an impaired short-latency afferent inhibition, which supported the cholinergic dysfunction in those patients developing cognitive decline; this was further supported in RBD patients in the context of PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0107" ref-type="bibr">107</xref></citation_analysis><citation_analysis attribute="negative"> As such, cholinergic dysfunction may substantially contribute to non-motor aspects of PD as well, raising also the hypothesis that RBD increased the risk of cognitive changes in PD.</citation_analysis></p>
        <p><citation_analysis attribute="neither">The second study found that iRBD patients exhibited an electrocortical profile similar to that observed in PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0108" ref-type="bibr">108</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, intracortical disinhibition was related to muscular tone change, which supports the model of retrograde influence of the brainstem to the cortex.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0109" ref-type="bibr">109</xref></citation_analysis><citation_analysis attribute="neither"> Therefore, an altered control in RBD, which would arise from the brainstem and ascend to the cortex, may determine both a reduced atonia during REM sleep and an imbalanced cortical disinhibition and hypofacilitation, favoring the former.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0108" ref-type="bibr">108</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">Recently, a direct comparison between iRBD and PDRBD revealed that both patient groups had a significantly decreased intracortical facilitation compared to healthy controls, thus sharing the involvement of glutamatergic transmission.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0110" ref-type="bibr">110</xref></citation_analysis><citation_analysis attribute="neither"> Finally, another report has recently compared PD without and with RBD: an enhancement of GABA-mediated and a reduction of glutamine-mediated activity was found in PDRBD only, thus suggesting a distinctive physiopathological processes in these subjects.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0111" ref-type="bibr">111</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">To date, no study has applied repetitive TMS in RBD or PDRBD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0112" ref-type="bibr">112</xref></citation_analysis></p>
      </sec>
      <sec id="s0005-s2003">
        <title>Vestibular Evoked Myogenic Potentials (VEMPs) and Other Brainstem Responses</title>
        <p><citation_analysis attribute="neither">Ocular (oVEMP), masseter (mVEMP), and cervical (cVEMP) VEMPs can provide an extensive evaluation of whole-length brainstem functioning, also allowing the detection of subtle changes in radiologically or clinically “mute” areas.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0113" ref-type="bibr">113</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">De Natale et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0114" ref-type="bibr">114</xref></citation_analysis><citation_analysis attribute="positive"> reported for the first time a significant alteration of VEMPs in iRBD subjects, especially for oVEMP and mVEMP, thus suggesting that synaptic and neuronal derangement was particularly evident in the upper areas of the brainstem, a finding which is in accordance with current physiopathology of RBD in PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0115" ref-type="bibr">115</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, the correlation between VEMP and RSWA may precede the progression from iRBD to neurodegeneration, whereas changes at the dopamine transporter scan would indicated a later stage.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0116" ref-type="bibr">116</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">Very recently, PD patients with RBD showed bilateral delays in cVEMP and oVEMP peak latencies with respect to PDnoRBD, whereas cVEMP features were also higher in PDRBD than in iRBD group.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0117" ref-type="bibr">117</xref></citation_analysis><citation_analysis attribute="neither"> Although follow-up studies are needed, this indicates that brainstem neurophysiology might reflect different disease involvement and that VEMPs can vary based on the occurrence of RBD in PD, even in its early stages.</citation_analysis></p>
        <p><citation_analysis attribute="neither">Both PD and RBD subjects exhibited altered blink and pupil behavior with respect to healthy controls.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0118" ref-type="bibr">118</xref></citation_analysis><citation_analysis attribute="neither"> Notably, since measures of RBD saccade were similar to those found in normal individuals, blink and pupil brain regions might be affected before those underlying saccadic control, thus making them potential prodromal markers of PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0119" ref-type="bibr">119</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, blink reflex parameters in PD did not relate to cognition or RBD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0120" ref-type="bibr">120</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">Recently, the pedunculopontine nucleus in dream-enacting motor behavior has been assessed through the prepulse modulation (PPM). PPM was altered in both RSWA and iRBD patients, while auditory startle reflex was increased in iRBD only, suggesting the presence of both differences and similarities in RSWA and iRBD pathophysiology.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0121" ref-type="bibr">121</xref></citation_analysis></p>
      </sec>
      <sec id="s0005-s2004">
        <title>Other Neurophysiological Investigations</title>
        <p><citation_analysis attribute="neither">Vegetative tests indicate that severity of autonomic dysfunction in iRBD seems to be intermediate between PD and normal values.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0122" ref-type="bibr">122</xref></citation_analysis><citation_analysis attribute="neither"> Overall, orthostatic hypotension and RBD produced both combined and individual detrimental consequences on disability in alpha-synucleinopathy, possibly reflecting a “malignant subtype” of PD, along with postural instability and early cognitive decline. The involvement of selected noradrenergic and cholinergic brainstem nuclei may be among the proposed underlying pathomechanisms.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0123" ref-type="bibr">123</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">Cortico-muscular coherence (CMC) is the functional correlate of connectivity between the primary motor cortex (as indexed by magnetoencephalography or EEG) and contralateral muscles during isometric activity.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0118" ref-type="bibr">118</xref></citation_analysis><citation_analysis attribute="neither"> Under normal condition, CMC significantly lowers during REM sleep with respect to wakefulness; conversely, in RBD, CMC during the REM sleep was found to be higher than in controls, thus hypothesizing that cortical locomotor drive was enhanced during REM sleep in this disorder.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0124" ref-type="bibr">124</xref></citation_analysis><citation_analysis attribute="positive"> These findings have been recently confirmed and extended by an independent study in which muscle atonia index, CMC, and cortico-cortical coherence revealed specific findings both in PDRBD and in iRBD groups.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0125" ref-type="bibr">125</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">Lastly, some studies assessed psychophysiologic parameters, eg, through the active and passive oddball P300 paradigm.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0126" ref-type="bibr">126</xref></citation_analysis><citation_analysis attribute="positive"> In iRBD, no difference was noted between patients and matched controls, at least at early-middle stages of the disease. Since cognitive alterations have been reported in RBD,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0127" ref-type="bibr">127</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0128" ref-type="bibr">128</xref></citation_analysis><citation_analysis attribute="positive"> event-related potentials using a cognitive task have been also tested. An occipital positive wave (P2) was found in PDRBD subjects, whereas it was nearly absent in healthy individuals. Of note, PDnoRBD were similar to controls, thus indicating that RBD may worsen the cortical dysfunction in PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0129" ref-type="bibr">129</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">It should be acknowledged that, despite a number of available markers derived from different neurophysiological techniques, not all of them seem to have a diagnostic value or a clear prognostic role in the monitoring of disease progression or response to therapy. This may be due, at least in part, to the limited sample size included in most studies and some aspects of study design themselves (eg, drug-naïve vs de novo patients, adequate comparisons, technical/procedural variability, magnitude of the results, etc.).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither"> Therefore, a combined use of neurophysiological and other, multidimensional, biomarkers, will be needed, especially in the case of RBD subtyping and differential diagnosis.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0130" ref-type="bibr">130</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0131" ref-type="bibr">131</xref></citation_analysis><citation_analysis attribute="positive"> For instance, using solid neurophysiological features, such as RSWA, in combination with other types of biomarkers might have a relevant role in the identification and characterization of RBD as a prodromal form of PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0132" ref-type="bibr">132</xref></citation_analysis><citation_analysis attribute="neither"> Nevertheless, longitudinal studies are required to verify whether the neurophysiological abnormalities detected at the early stages of RBD by EEG, TMS, VEMP, and other techniques correlate with clinical progression of RBD.</citation_analysis></p>
        <p><citation_analysis attribute="positive"><xref rid="t0002" ref-type="table">Table 2</xref></citation_analysis><citation_analysis attribute="positive"> summarizes main findings obtained from different neurophysiological techniques in patients with isolated REM sleep behavior disorder (iRBD), Parkinson’s disease with RBD (PDRBD), and Parkinson’s disease without RBD (PDnoRBD). </citation_analysis><citation_analysis attribute="positive"><xref rid="f0001" ref-type="fig">Figure 1</xref></citation_analysis><citation_analysis attribute="positive"> summarizes the neurophysiological findings in iRBD, PDRBD and PDnoRBD population.</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0002"><label>Table 2</label><caption><p><citation_analysis attribute="neither">Main Findings Obtained from Different Neurophysiological Techniques in Patients with Isolated REM Sleep Behavior Disorder (iRBD), Parkinson’s Disease with RBD (PDRBD), and Parkinson’s Disease Without RBD (PDnoRBD)</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Technique</th><th align="center" rowspan="1" colspan="1">iRBD</th><th align="center" rowspan="1" colspan="1">PDRBD</th><th align="center" rowspan="1" colspan="1">PDnoRBD</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Electroencephalography (EEG)</td><td rowspan="1" colspan="1">Diffuse EEG slowing, more in occipital; higher delta and theta power, theta-band bursts; decreased alpha-band burst<break/>Lack of suppression of beta rhythms during phasic REM (increased cortical arousal)<break/>Increased EEG instability during REM<break/>Decreased fast, but increased slow, sleep spindles, or global density, during eye- closed wakefulness</td><td rowspan="1" colspan="1">Higher theta power; slowing of occipital frequency correlated with cognitive decline<break/>Global decrease in spindle density<break/>Higher delta and lower alpha power, more in central and occipital regions during phasic REM<break/>EEG slowing, especially during the phasic period, may predict phenoconversion rather than subjective RBD severity</td><td rowspan="1" colspan="1">No or mild/unspecific slowing</td></tr><tr><td rowspan="1" colspan="1">Motor evoked potentials (MEPs)</td><td rowspan="1" colspan="1">Reduced short-latency afferent inhibition, supporting cholinergic and cognitive dysfunction<break/>MEP disinhibition and hypofacilitation; correlation between disinhibition and muscle tone alteration</td><td rowspan="1" colspan="1">Reduced short-latency afferent inhibition, supporting cholinergic and cognitive dysfunction<break/>Increased MEP inhibition and decreased facilitation (GABAergic and glutaminergic change)</td><td rowspan="1" colspan="1">Lack of MEP intracortical facilitation, suggesting a more severe impairment of glutaminergic transmission than in PDRBD</td></tr><tr><td rowspan="1" colspan="1">Vestibular evoked myogenic potentials (VEMPs): masseter (mVEMP), ocular (oVEMP), and cervical (cVEMP) VEMPs</td><td rowspan="1" colspan="1">Severe alteration of mVEMP and oVEMP, implying the involvement of upper brainstem areas; correlation between REM sleep without atonia (RSWA) and VEMP</td><td rowspan="1" colspan="1">Delayed cVEMP and oVEMP compared to PDnoRBD; cVEMP scored higher in PDRBD than iRBD<break/>Phasic RSWA correlated with cVEMP; tonic RSWA with left oVEMP</td><td rowspan="1" colspan="1">No significant delay in cVEMP and oVEMP, bilaterally, compared to PDRBD</td></tr><tr><td rowspan="1" colspan="1">Other brainstem responses</td><td rowspan="1" colspan="1">Pupil and blink areas impacted before saccadic control (PD prodromes?)<break/>Abnormal prepulse modulation and auditory startle reflex</td><td rowspan="1" colspan="1">Altered pupil and blink behavior<break/>Blink reflex parameters did not relate to RBD</td><td rowspan="1" colspan="1">Startle reflex hyporeactivity</td></tr><tr><td rowspan="1" colspan="1">Vegetative tests</td><td rowspan="1" colspan="1">Dysfunction of intermediate severity between controls and PD</td><td rowspan="1" colspan="1">Autonomic dysfunction, often more severe than in PDnoRBD</td><td rowspan="1" colspan="1">Autonomic dysfunction, often less severe than in PDRBD</td></tr><tr><td rowspan="1" colspan="1">Cortico-muscular coherence (CMC)</td><td rowspan="1" colspan="1">Higher during REM sleep than controls (increased cortical locomotor drive)</td><td rowspan="1" colspan="1">Distinctive features of muscle atonia index, CMC, and cortico-cortical coherence</td><td rowspan="1" colspan="1">No comparison available between PDRBD and PDnoRBD</td></tr><tr><td rowspan="1" colspan="1">Event-related potentials</td><td rowspan="1" colspan="1">No difference compared to controls, at least at the early-middle stages</td><td rowspan="1" colspan="1">Occipital positive wave, nearly absent in controls.</td><td rowspan="1" colspan="1">No difference compared to PDRBD and controls</td></tr></tbody></table></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0001" fig-type="figure"><label>Figure 1</label><caption><p><citation_analysis attribute="positive">Neurophysiological findings in RBD population: Overview of the main electrophysiological techniques that have provided insights on the neurophysiological basis of RBD. Cortical activity is explored with conventional electroencephalography (EEG) and event-related potentials (ERPs). Cortico-muscular coherence (CMC) relates to the synchrony in the neural activity of brain’s cortical areas and muscles, thus allowing to study the neural control of movement. Motor evoked potentials (MEPs) to transcranial magnetic stimulation (TMS) specifically probe the excitation state of the primary motor cortex. Neurovegetative tests can be applied to functionally assess the hypothalamus, a key region for the central control of the autonomic nervous system. Finally, vestibular evoked myogenic potentials (VEMPs), as well as blink and startle reflexes, are suitable tools to evaluate the brainstem excitability.</citation_analysis></p></caption><graphic xlink:href="NSS-15-333-g0001" content-type="print-only" position="float"/></fig></citation_analysis></p>
      </sec>
    </sec>
    <sec id="s0006">
      <title>Parkinson’s Disease RBD Phenotype: Pharmacological Management</title>
      <p><citation_analysis attribute="positive">While many medications have been found to have some therapeutic effects on RBD, the overall effects of treatment are still unsatisfactory.</citation_analysis></p>
      <p><citation_analysis attribute="neither">Clonazepam, a long-acting sedative benzodiazepine, is the first option to treat RBD,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0133" ref-type="bibr">133</xref></citation_analysis><citation_analysis attribute="positive"> however, its mechanism of action is still unclear and the proof of its efficacy for RBD relies on many observational studies, mainly retrospective cohorts and case-series.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0134" ref-type="bibr">134</xref></citation_analysis><citation_analysis attribute="neither"> Furthermore, most studies used small samples and did not contain quantitative measurements.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Clonazepam can dramatically decrease the phasic EMG activity on polysomnography, while there is insufficient evidence of reduction in the objective or subjective severity of RBD. It has been shown that Clonazepam can reduce phasic twitching in RBD without re-establish REM sleep muscle atonia.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0089" ref-type="bibr">89</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">A recent randomized placebo-controlled trial was conducted in order to determine the efficacy and safety of clonazepam for the treatment of probable RBD (pRBD) in patients with PD.</citation_analysis></p>
      <p><citation_analysis attribute="positive">The primary outcome was the Clinical Global Impressions Improvement score at week four. No significant difference in scores between the clonazepam and placebo groups was detected. The conclusions of this study must be interpreted cautiously. In fact, the authors recruited pRBD patients without VPSG confirmation.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0090" ref-type="bibr">90</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Very few studies have examined the effects of clonazepam on polysomnographic parameters. It has been previously reported in iRBD patients that 0.5 to 1 mg per day of clonazepam significantly improved the percentage of stage 2 sleep compared to baseline.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0135" ref-type="bibr">135</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0136" ref-type="bibr">136</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">However, clonazepam can worsen cognitive impairment and sleep apnea and it should be used cautiously in patients with these symptoms.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0011" ref-type="bibr">11</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Melatonin is recommended as a safe complementary treatment option for patients with RBD. Melatonin and clonazepam were found to be effective in reducing the symptoms of RBD, but melatonin was better tolerated with fewer adverse reactions and greater reduction in injury.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0137" ref-type="bibr">137</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Few studies are available on the therapeutic effects of melatonin on RBD. Melatonin is a hormone secreted by the pineal gland in a circadian pattern, influenced by dark environments with levels peaking during the middle of the night.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0134" ref-type="bibr">134</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Some studies have shown that 3 to 12 mg per day of melatonin can reduce RBD-related injuries with little side effects, though the numbers of RBD events has not decreased.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0134" ref-type="bibr">134</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0137" ref-type="bibr">137–140</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Evidence suggests that melatonin improves RBD by reducing the tonic EMG activity during REM sleep, the inhibition of gamma-aminobutyric acid, the stabilization of the circadian rhythm, the increased striatal bioavailability of L-dopa and modulation of skeletal muscles.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0140" ref-type="bibr">140</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">A recent randomized double-blind placebo-controlled trial was conducted to evaluate the efficacy of 4 mg slow-release melatonin in 30 patients with PD and RBD. The primary outcome was the difference in the total number of RBD events as assessed by the weekly CIRUS‐RBD Questionnaire (item - 4). The trial shows that melatonin 4 mg per day did not have a large effect on the reduction of RBD in PD patients, but it is still unknown if other doses are ineffective.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0141" ref-type="bibr">141</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Ramelteon is an agonist of melatonin receptors that has a positive impact on idiopathic and secondary RBD. Recently, two studies have shown that Ramelteon improve clinical RBD symptoms and decrease RWA in two patients for which conventional therapies were contraindicated.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0142" ref-type="bibr">142</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0143" ref-type="bibr">143</xref></citation_analysis><citation_analysis attribute="neither"> Kashihara et al showed that ramelteon improve nighttime sleep and PD motor performances according to UPDRS Part III scores.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0142" ref-type="bibr">142</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Randomized controlled studies of dopaminergic agonists for RBD in PD are still missing. Available uncontrolled studies, including those using newer dopaminergic agonists, are considered inconclusive.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0134" ref-type="bibr">134</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Dusek et al evaluated the impact of slow-release and immediate-release ropinirole on PD-related sleep disorders, including RBD. A total of 33 PD patients initially receiving immediate release ropinirole, followed by five to thirteen weeks of prolonged release ropinirole were investigated. The secondary outcome was to investigate the effects of slow-release versus immediate-release ropinirole on RBD symptoms assessed by RBDSQ. There was no statistically significant improvement in RBDSQ scores and RSWA.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0144" ref-type="bibr">144</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">An open-label study was conducted to assess the effect of rotigotine on RBD in PD patients PDRBD patients. Subjects were treated for approximately 28 weeks at increasing doses from 2 to 16 mg/24 h according to parkinsonism response and tolerance. Patients were evaluated before and after treatment using the PSG, RBDSS, PDSS-2 and the REM sleep behavior disorder questionnaire-Hong Kong (RBDQ-HK) scales. At the end of the treatment, the PDSS-2, the overall RBDQ-HK scale scores decreased significantly. However, there were no objective changes in the motor variables assessed by PSG (percentage of RSWA) or RBDS.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0145" ref-type="bibr">145</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Pramipexole affects REM sleep by increasing REM sleep latency and reducing total REM sleep time.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0146" ref-type="bibr">146</xref></citation_analysis><citation_analysis attribute="neither"> In patients with idiopathic RBD, pramipexole significantly decreased the frequency and severity of RBD symptoms and remained effective for 25 months.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0147" ref-type="bibr">147</xref></citation_analysis><citation_analysis attribute="neither"> In contrast, PD patients with RBD did not have any benefit.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0148" ref-type="bibr">148</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">In a prospective study, 11 PDRBD patients on levodopa monotherapy were treated with pramipexole. The effects on RBD were evaluated before and 3 months after stable pramipexole therapy through patient and bed partner interviews and blind assessment of video-polysomnography (VPSG) measures.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0134" ref-type="bibr">134</xref></citation_analysis><citation_analysis attribute="positive"> Before and 3 months after stable pramipexole therapy, effects on RBD were assessed through patients and bed-partners interviews and VPSG measures.</citation_analysis></p>
      <p><citation_analysis attribute="positive">No significant changes in severity and frequency of RBD related motor and vocal behavior as well as frequency of unpleasant dreams were reported by patients and bed-partners. The VPSG analyses showed no difference in sleep measures related to RBD and the severity of abnormal behavior revealed by the videotape.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0148" ref-type="bibr">148</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Currently rotigotine is the only dopaminergic agonist that has led to an improvement in the RBD symptoms in PD patients. That improvement appears to be due by improved nocturnal motor symptoms.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0149" ref-type="bibr">149</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Donepezil and rivastigmine can also be considered for treating patients with RBD, particularly in patients with cognitive impairment.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0150" ref-type="bibr">150</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">The cholinesterase inhibitor rivastigmine has been used as a substitute treatment to melatonin and clonazepam. We found only one crossover double-blind study on the efficacy of rivastigmine in reducing the frequency of RBD episodes in PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0150" ref-type="bibr">150</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Rivastigmine was administered through a transdermal patch (4.6 mg/24 hours) for 3 weeks to non demented PDRBD patients that were refractory to melatonin and clonazepam.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Rivastigmine has demonstrated a beneficial effect on the reduction of RBD events and the improvement of subjective night sleep, proving to be a viable alternative in the control of RBD in patients resistant to conventional therapies. Unfortunately, the sample size was too small to reach definitive conclusions.</citation_analysis></p>
      <p><citation_analysis attribute="positive">These preliminary data should be evaluated cautiously, as cases of RBD induced by acetylcholinesterase inhibitors have been reported.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Interestingly, a reduction in the frequency of refractory RBD episodes have been reported in subjects with mild cognitive impairment, who participated in a placebo-controlled, cross-over pilot trial of Rivastigmine.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0151" ref-type="bibr">151</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Moreover, the donepezil, another acetylcholinesterase inhibitor, has shown an effectiveness in improving RBD symptoms.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0152" ref-type="bibr">152</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Memantine may reduce the dream enactment frequency and the total REM sleep time.</citation_analysis></p>
      <p><citation_analysis attribute="neither">A randomized controlled and multicenter study was conducted in order to assess the effectiveness of memantine on sleep disorders, including RBD in PD patients with dementia or DLB patients.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0134" ref-type="bibr">134</xref></citation_analysis><citation_analysis attribute="positive"> After 24 weeks of treatment, subjects who received memantine significantly improved restlessness during sleep when compared to placebo. Nevertheless, the absence of PSG, both at the screening stage and at the follow-up, compromised the reliability of these results. Indeed, the RBD was assessed through a single question “Is the patient physically active during sleep?”.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0153" ref-type="bibr">153</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">In a pilot study the use of cannabidiol (CBD) in PDRBD patients at doses ranging from 75 to 300 mg for six weeks, caused a reduction of up to 80% in the frequency of the nocturnal behaviors assessed through the sleep diary.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0154" ref-type="bibr">154</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Other drugs such as zopiclone (doses ranging from 3.75 to 7.5 mg) and sodium oxybate (doses ranging from 3 to 9 g) are also effective in RBD therapy, but their effectiveness has not been demonstrated in PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0155" ref-type="bibr">155</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Some case reports indicate that 10 mg daily of temazepam may be effective in treating RBD symptoms.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0155" ref-type="bibr">155</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">There are also cases or small series that show the possible effectiveness of carbamazepine</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0156" ref-type="bibr">156</xref></citation_analysis><citation_analysis attribute="neither"> and gabapentin</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0157" ref-type="bibr">157</xref></citation_analysis><citation_analysis attribute="neither"> on RBD symptoms.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Antipsychotic drugs like quetiapine and clozapine have also been shown to be effective in patients with iRBD. However, there are no robust reports about their impact on RBD in PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0158" ref-type="bibr">158</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">In a recent randomized, double-blind placebo-controlled crossover trial, the 5-hydroxytryptophan (a precursor of serotonin) increased the overall percentage of REM sleep stage without a related increase of RBD episodes. Moreover, the self-reported RBD frequency and severity were improved during 5-hydroxytryptophan treatment.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0159" ref-type="bibr">159</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">The therapeutic effects of the Yi-Gan San, an herbal with gabaergic and serotonergic properties, has been described in iRBD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0160" ref-type="bibr">160</xref></citation_analysis></p>
      <p><citation_analysis attribute="negative">As evidenced by previous studies, there have been major limitations in subjective quantification of RBD symptoms. In a recent observational cohort study a newly developed RBD symptom severity scale (Ikelos-RS) has been used in a large group of patients with iRBD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0161" ref-type="bibr">161</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Moreover, a self-administered modified RBDQ scale (the timeframe of the scale were modified into the past 3-month period) has proven to be a sensitive tool for monitoring treatment progress over a brief period of time.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0135" ref-type="bibr">135</xref></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><xref rid="t0003" ref-type="table">Table 3</xref></citation_analysis><citation_analysis attribute="neither"> summarizes the pharmacological treatment of RBD in PD patients.</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0003"><label>Table 3</label><caption><p><citation_analysis attribute="neither">Pharmacological Treatments of RBD in PD Patients</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Reccomended Dose</th><th rowspan="1" colspan="1">Benefits</th><th rowspan="1" colspan="1">Side Effects</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Clonazepam</td><td rowspan="1" colspan="1">0.5–2 mg</td><td rowspan="1" colspan="1">Decrease RBD events; improve subjective nocturnal sleep; reduce phasic EMG activity</td><td rowspan="1" colspan="1">Morning sedation; falls; worsening of OSA(Obstructive Sleep Apnea); diurnal drowsiness.</td></tr><tr><td rowspan="1" colspan="1">Melatonin</td><td rowspan="1" colspan="1">3–12 mg</td><td rowspan="1" colspan="1">Reduce injuries associated with RBD; improve subjective night sleep</td><td rowspan="1" colspan="1">Light headache; daytime sleepiness; fatigue.</td></tr><tr><td rowspan="1" colspan="1">Ramelteon</td><td rowspan="1" colspan="1">8 mg</td><td rowspan="1" colspan="1">Decrease RBD episodes; improve subjective nighttime sleep; improve PD motor performances</td><td rowspan="1" colspan="1">Daytime sleepiness; aggravation of constipation; nausea; dizziness; delirium.</td></tr><tr><td rowspan="1" colspan="1">Rotigotine</td><td rowspan="1" colspan="1">2–16 mg</td><td rowspan="1" colspan="1">Decrease RBD events (no changes in percentage of RWA); improve PD motor and non-motor symptom; helps reduce pain.</td><td rowspan="1" colspan="1">Localized reactions; dyskinesia; headache; dizziness; diurnal drowsiness; tiredness; nausea.</td></tr><tr><td rowspan="1" colspan="1">Rivastigmine (patch)</td><td rowspan="1" colspan="1">4.6 mg/24 hours</td><td rowspan="1" colspan="1">Decrease RBD episodes; improve subjective nighttime sleep</td><td rowspan="1" colspan="1">Cholinergic adverse effects</td></tr><tr><td rowspan="1" colspan="1">Memantine</td><td rowspan="1" colspan="1">20 mg</td><td rowspan="1" colspan="1">Reduction of RBD events; improvement in cognitive functioning</td><td rowspan="1" colspan="1">Bradycardia; nausea</td></tr><tr><td rowspan="1" colspan="1">Cannabidiol</td><td rowspan="1" colspan="1">75–300 mg</td><td rowspan="1" colspan="1">Reduction of RBD-related events</td><td rowspan="1" colspan="1">No side effects.</td></tr><tr><td rowspan="1" colspan="1">5-hydroxytryptophan</td><td rowspan="1" colspan="1">50 mg−150 mg</td><td rowspan="1" colspan="1">Improvement of self-reported RBD frequency and severity</td><td rowspan="1" colspan="1">No side effects.</td></tr><tr><td rowspan="1" colspan="1">Gabapentin</td><td rowspan="1" colspan="1">300–800 mg</td><td rowspan="1" colspan="1">Reduction of RBD events</td><td rowspan="1" colspan="1">No side effects</td></tr><tr><td rowspan="1" colspan="1">Carbamazepine</td><td rowspan="1" colspan="1">300–800 mg</td><td rowspan="1" colspan="1">Improvement of RBD symptoms </td><td rowspan="1" colspan="1">No side effects</td></tr><tr><td rowspan="1" colspan="1">Zopiclone </td><td rowspan="1" colspan="1">3.75–7.5 mg</td><td rowspan="1" colspan="1">Reduction of RBD events</td><td rowspan="1" colspan="1">No side effects</td></tr><tr><td rowspan="1" colspan="1">Sodium oxybate</td><td rowspan="1" colspan="1">3–9 g</td><td rowspan="1" colspan="1">Long-term clinical improvement of RBD symptoms</td><td rowspan="1" colspan="1">No side effects</td></tr><tr><td rowspan="1" colspan="1">Temazepam</td><td rowspan="1" colspan="1">10 mg daily</td><td rowspan="1" colspan="1">Reduction of RBD events</td><td rowspan="1" colspan="1">No side effects</td></tr><tr><td rowspan="1" colspan="1">Yi-Gan San</td><td rowspan="1" colspan="1">2.5 g 3 times daily</td><td rowspan="1" colspan="1">Complete or significant improvement of RBD symptoms</td><td rowspan="1" colspan="1">No side effects.</td></tr></tbody></table></table-wrap></citation_analysis></p>
    </sec>
    <sec id="s0007">
      <title>Parkinson’s Disease RBD Phenotype: Non-Pharmacological Management</title>
      <p><citation_analysis attribute="negative">RBD patients, both isolated and associated with PD, are at risk of injuries, to themselves or to bedpartner, related to complex-motor dream-enacting behaviors.</citation_analysis></p>
      <p><citation_analysis attribute="negative">Sleep protection measures are warranted to minimize the risk of injury to the patient and bedpartner. In order to improve the security of the bedroom, protective strategies such as the placement of mattresses on the ground or the securing of windows should be considered.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0162" ref-type="bibr">162</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Regular physical exercise is advisable in patients with PD and sleep disorders. In a recent meta-analysis has been found that exercise had a significant positive effect on subjective sleep quality in people with PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0163" ref-type="bibr">163</xref></citation_analysis><citation_analysis attribute="positive"> Furthermore, it has been shown that intensive exercise may play a protective role through direct modulation of the accumulation of multiple proteins associated with neurodegenerative process. Since RBD is an early occurrence of a neurodegenerative disease caused by pathologic aggregates of α-synuclein, it would make sense to examine the potential neuroprotective effects of exercise with RBD patients.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0164" ref-type="bibr">164</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">A reduced prevalence of prodromal features associated with PD in patients who were more physically active has been described in a recent study. PD subjects who maintained a high level of physical activity during follow-up were less susceptible to be affected by RBD symptoms.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0165" ref-type="bibr">165</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">The benefits of multidisciplinary intensive rehabilitation treatment (MIRT) on sleep disorders in PD have been highlighted.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0140" ref-type="bibr">140</xref></citation_analysis><citation_analysis attribute="positive"> Specifically, the rehabilitation treatment included a wide range of aerobic exercises combined with relaxation techniques, stretching exercises, stability exercises focused on balance and gait.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0166" ref-type="bibr">166</xref></citation_analysis><citation_analysis attribute="neither"> However, research on exercise aimed at improving sleep disorders, including RBD, is still limited. Whereby the exercise modality, frequency, duration and intensity needed for sleep optimization are not known.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0167" ref-type="bibr">167</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Patients with RBD have a low arousal threshold of REM sleep. A reduction in RBD symptoms and sleep-related injuries was reported in four patients with RBD through the use of customized bed alarms with a familiar voice to deliver a soothing message at the beginning of dream enactment behaviors (level III of evidence).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0168" ref-type="bibr">168</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Many lines of evidence have demonstrated that deep brain stimulation (DBS) can ameliorate sleep quality in patients with PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0169" ref-type="bibr">169</xref></citation_analysis><citation_analysis attribute="positive"> Some studies shown that DBS of the PPN may modulate some non-motor functions, including REM sleep, mood, arousal and sleep-wake cycle.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0170" ref-type="bibr">170</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0171" ref-type="bibr">171</xref></citation_analysis><citation_analysis attribute="neither"> However, some studies suggest that PPN-DBS could contribute to worsening RBD in PD patients.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0172" ref-type="bibr">172</xref></citation_analysis></p>
    </sec>
    <sec id="s0008">
      <title>Conclusion</title>
      <p><citation_analysis attribute="negative">RBD offers a precious insight for the management of PD: not only its presence allows to individuate a population at risk of developing the disease, but also when the disease is conclamated it’s connected to a more aggressive phenotype for both motor and non-motor symptoms, especially cognitive impairment.</citation_analysis></p>
      <p><citation_analysis attribute="positive">This can guide the physician to a more tailored treatment and follow up of PD patients, focusing on early intervention for the prevention and management of cognitive impairment.</citation_analysis></p>
      <p><citation_analysis attribute="neither">Finally, iRBD is a unique cohort of patients ready to access to future trials of neuroprotective and disease modifying therapy.</citation_analysis></p>
      <p><citation_analysis attribute="negative">Future research should focus on the creation of combination models and stratification of biomarkers in order to have easily accessible and reliable tools to select patients at risk of phenoconversion or to individuate early signs of cognitive impairment.</citation_analysis></p>
      <sec id="s0008-s2001">
        <title>Final Remarks</title>
        <p><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><list list-type="bullet"><list-item><p><citation_analysis attribute="negative">iRBD has an estimated risk to develop a neurodegenerative disease up to 90%, thus representing an ideal condition for testing new neuroprotective and disease-modifying drug.</citation_analysis></p></list-item><list-item><p><citation_analysis attribute="neither">RBD seems to be a key clinical indicator of a body-first/diffuse-malignant phenotype, characterized by a more widespread neurodegenerative process and worse motor and non-motor symptoms of PD.</citation_analysis></p></list-item><list-item><p><citation_analysis attribute="neither">RSWA, the neurophysiological hallmark of RBD, correlates with worse cognitive performances and MCI, and/or impaired attention and executive functions might predict early conversion to dementia.</citation_analysis></p></list-item><list-item><p><citation_analysis attribute="positive">Some medications and non-pharmacological options have been found to have some therapeutic effects on RBD, although their overall impact is still unsatisfactory and, therefore, new evidence-based approaches are needed.</citation_analysis></p></list-item><list-item><p><citation_analysis attribute="neither">Several clinical, neurophysiological, neuroimaging, biological, and genetic biomarkers have been individuated, although a consensus on the identification of one or more biomarkers to be translated in clinical practice is still lacking.</citation_analysis></p></list-item></list></citation_analysis></p>
      </sec>
    </sec>
  </body>
  <back>
    <sec sec-type="COI-statement" id="s0009">
      <title>Disclosure</title>
      <p><citation_analysis attribute="neither">The authors report no conflicts of interest in this work.</citation_analysis></p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="cit0001">
        <label>1.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Matar</surname>
<given-names>E</given-names></string-name>, <string-name><surname>McCarter</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>St Louis</surname>
<given-names>EK</given-names></string-name>, <string-name><surname>Lewis</surname>
<given-names>SJG</given-names></string-name>. <article-title>Current Concepts and Controversies in the Management of REM Sleep Behavior Disorder</article-title>. <source><italic toggle="yes">Neurotherapeutics</italic></source>. <year>2021</year>;<volume>18</volume>(<issue>1</issue>):<fpage>107</fpage>–<lpage>123</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13311-020-00983-7</pub-id><pub-id pub-id-type="pmid">33410105</pub-id></mixed-citation>
      </ref>
      <ref id="cit0002">
        <label>2.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Schenck</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, et al. <article-title>REM sleep behaviour disorder</article-title>. <source><italic toggle="yes">Nat Rev Dis Primers</italic></source>. <year>2018</year>;<volume>4</volume>(<issue>1</issue>):<fpage>19</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41572-018-0016-5</pub-id><pub-id pub-id-type="pmid">30166532</pub-id></mixed-citation>
      </ref>
      <ref id="cit0003">
        <label>3.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>. <article-title>The REM sleep circuit and how its impairment leads to REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Cell Tissue Res</italic></source>. <year>2018</year>;<volume>373</volume>(<issue>1</issue>):<fpage>245</fpage>–<lpage>266</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00441-018-2852-8</pub-id><pub-id pub-id-type="pmid">29846796</pub-id></mixed-citation>
      </ref>
      <ref id="cit0004">
        <label>4.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Santamaria</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Tolosa</surname>
<given-names>E</given-names></string-name>. <article-title>The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2009</year>;<volume>13</volume>(<issue>6</issue>):<fpage>385</fpage>–<lpage>401</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2008.11.003</pub-id><pub-id pub-id-type="pmid">19362028</pub-id></mixed-citation>
      </ref>
      <ref id="cit0005">
        <label>5.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Haba-Rubio</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Marti-Soler</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Marques-Vidal</surname>
<given-names>P</given-names></string-name>, et al. <article-title>Prevalence and determinants of periodic limb movements in the general population: PLMS in the General Population</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2016</year>;<volume>79</volume>(<issue>3</issue>):<fpage>464</fpage>–<lpage>474</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.24593</pub-id><pub-id pub-id-type="pmid">26703954</pub-id></mixed-citation>
      </ref>
      <ref id="cit0006">
        <label>6.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Pujol</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pujol</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Alonso</surname>
<given-names>T</given-names></string-name>, et al. <article-title>Idiopathic REM sleep behavior disorder in the elderly Spanish community: a primary care center study with a two-stage design using video-polysomnography</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2017</year>;<volume>40</volume>:<fpage>116</fpage>–<lpage>121</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2017.07.021</pub-id><pub-id pub-id-type="pmid">29042180</pub-id></mixed-citation>
      </ref>
      <ref id="cit0007">
        <label>7.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Santamaria</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Tolosa</surname>
<given-names>E</given-names></string-name>. <article-title>Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions</article-title>. <source><italic toggle="yes">Lancet Neurol</italic></source>. <year>2016</year>;<volume>15</volume>(<issue>4</issue>):<fpage>405</fpage>–<lpage>419</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(16)00057-0</pub-id><pub-id pub-id-type="pmid">26971662</pub-id></mixed-citation>
      </ref>
      <ref id="cit0008">
        <label>8.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Högl</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Arnulf</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Bergmann</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Rapid eye movement sleep behaviour disorder: past, present, and future</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2022</year>;<volume>31</volume>:<fpage>4</fpage>. doi:<pub-id pub-id-type="doi">10.1111/jsr.13612</pub-id></mixed-citation>
      </ref>
      <ref id="cit0009">
        <label>9.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fereshtehnejad</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Zeighami</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Dagher</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>. <article-title>Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2017</year>;<volume>140</volume>(<issue>7</issue>):<fpage>1959</fpage>–<lpage>1976</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awx118</pub-id><pub-id pub-id-type="pmid">28549077</pub-id></mixed-citation>
      </ref>
      <ref id="cit0010">
        <label>10.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Marras</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chaudhuri</surname>
<given-names>KR</given-names></string-name>. <article-title>Nonmotor features of ParkinsonParkinson’s disease subtypes</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2016</year>;<volume>31</volume>(<issue>8</issue>):<fpage>1095</fpage>–<lpage>1102</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.26510</pub-id><pub-id pub-id-type="pmid">26861861</pub-id></mixed-citation>
      </ref>
      <ref id="cit0011">
        <label>11.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Schenck</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Bundlie</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Mahowald</surname>
<given-names>MW</given-names></string-name>. <article-title>Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>1996</year>;<volume>46</volume>(<issue>2</issue>):<fpage>388</fpage>–<lpage>393</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.46.2.388</pub-id><pub-id pub-id-type="pmid">8614500</pub-id></mixed-citation>
      </ref>
      <ref id="cit0012">
        <label>12.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Braak</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Del Tredici</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Rüb</surname>
<given-names>U</given-names></string-name>, <string-name><surname>de Vos</surname>
<given-names>RAI</given-names></string-name>, <string-name><surname>Jansen Steur</surname>
<given-names>ENH</given-names></string-name>, <string-name><surname>Braak</surname>
<given-names>E</given-names></string-name>. <article-title>Staging of brain pathology related to sporadic Parkinson’s disease</article-title>. <source><italic toggle="yes">Neurobiol Aging</italic></source>. <year>2003</year>;<volume>24</volume>(<issue>2</issue>):<fpage>197</fpage>–<lpage>211</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0197-4580(02</pub-id><pub-id pub-id-type="pmid">12498954</pub-id></mixed-citation>
      </ref>
      <ref id="cit0013">
        <label>13.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Valencia Garcia</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Brischoux</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Clément</surname>
<given-names>O</given-names></string-name>, et al. <article-title>Ventromedial medulla inhibitory neuron inactivation induces REM sleep without atonia and REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Nat Commun</italic></source>. <year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>504</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-017-02761-0</pub-id><pub-id pub-id-type="pmid">29402935</pub-id></mixed-citation>
      </ref>
      <ref id="cit0014">
        <label>14.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Braak</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Ghebremedhin</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Rüb</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Bratzke</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Del Tredici</surname>
<given-names>K</given-names></string-name>. <article-title>Stages in the development of Parkinson’s disease-related pathology</article-title>. <source><italic toggle="yes">Cell Tissue Res</italic></source>. <year>2004</year>;<volume>318</volume>(<issue>1</issue>):<fpage>121</fpage>–<lpage>134</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00441-004-0956-9</pub-id><pub-id pub-id-type="pmid">15338272</pub-id></mixed-citation>
      </ref>
      <ref id="cit0015">
        <label>15.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hawkes</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Del Tredici</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Braak</surname>
<given-names>H</given-names></string-name>. <article-title>Parkinson’s disease: a dual-hit hypothesis</article-title>. <source><italic toggle="yes">Neuropathol Appl Neurobiol</italic></source>. <year>2007</year>;<volume>33</volume>(<issue>6</issue>):<fpage>599</fpage>–<lpage>614</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2990.2007.00874.x</pub-id><pub-id pub-id-type="pmid">17961138</pub-id></mixed-citation>
      </ref>
      <ref id="cit0016">
        <label>16.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Van Den Berge</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Ulusoy</surname>
<given-names>A</given-names></string-name>. <article-title>Animal models of brain-first and body-first Parkinson’s disease</article-title>. <source><italic toggle="yes">Neurobiol Dis</italic></source>. <year>2022</year>;<volume>163</volume>:<fpage>105599</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nbd.2021.105599</pub-id><pub-id pub-id-type="pmid">34952161</pub-id></mixed-citation>
      </ref>
      <ref id="cit0017">
        <label>17.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Attems</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Jellinger</surname>
<given-names>KA</given-names></string-name>. <article-title>The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease</article-title>. <source><italic toggle="yes">Neuropathol Appl Neurobiol</italic></source>. <year>2008</year>;<volume>34</volume>(<issue>4</issue>):<fpage>466</fpage>–<lpage>467</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2990.2008.00937.x</pub-id><pub-id pub-id-type="pmid">18282157</pub-id></mixed-citation>
      </ref>
      <ref id="cit0018">
        <label>18.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jellinger</surname>
<given-names>KA</given-names></string-name>. <article-title>Is Braak staging valid for all types of Parkinson’s disease?</article-title>
<source><italic toggle="yes">J Neural Transm</italic></source>. <year>2019</year>;<volume>126</volume>(<issue>4</issue>):<fpage>423</fpage>–<lpage>431</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00702-018-1898-9</pub-id><pub-id pub-id-type="pmid">29943229</pub-id></mixed-citation>
      </ref>
      <ref id="cit0019">
        <label>19.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Borghammer</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Van Den Berge</surname>
<given-names>N</given-names></string-name>. <article-title>Brain-First versus Gut-First Parkinson’s Disease: a Hypothesis</article-title>. <source><italic toggle="yes">JPD</italic></source>. <year>2019</year>;<volume>9</volume>(<issue>s2</issue>):<fpage>S281</fpage>–<lpage>S295</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JPD-191721</pub-id><pub-id pub-id-type="pmid">31498132</pub-id></mixed-citation>
      </ref>
      <ref id="cit0020">
        <label>20.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Horsager</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Andersen</surname>
<given-names>KB</given-names></string-name>, <string-name><surname>Knudsen</surname>
<given-names>K</given-names></string-name>, et al. <article-title>Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2020</year>;<volume>143</volume>(<issue>10</issue>):<fpage>3077</fpage>–<lpage>3088</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awaa238</pub-id><pub-id pub-id-type="pmid">32830221</pub-id></mixed-citation>
      </ref>
      <ref id="cit0021">
        <label>21.</label>
        <mixed-citation publication-type="journal"><string-name><surname>McKenna</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Peever</surname>
<given-names>J</given-names></string-name>. <article-title>Degeneration of rapid eye movement sleep circuitry underlies rapid eye movement sleep behavior disorder</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2017</year>;<volume>32</volume>(<issue>5</issue>):<fpage>636</fpage>–<lpage>644</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.27003</pub-id><pub-id pub-id-type="pmid">28394031</pub-id></mixed-citation>
      </ref>
      <ref id="cit0022">
        <label>22.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Leclair-Visonneau</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Clairembault</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Coron</surname>
<given-names>E</given-names></string-name>, et al. <article-title>REM sleep behavior disorder is related to enteric neuropathology in Parkinson disease</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2017</year>;<volume>89</volume>(<issue>15</issue>):<fpage>1612</fpage>–<lpage>1618</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000004496</pub-id><pub-id pub-id-type="pmid">28887374</pub-id></mixed-citation>
      </ref>
      <ref id="cit0023">
        <label>23.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Adler</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Dugger</surname>
<given-names>BN</given-names></string-name>, et al. <article-title>REM sleep behavior disorder and neuropathology in Parkinson’s disease: RBD in PD</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2015</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1413</fpage>–<lpage>1417</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.26347</pub-id><pub-id pub-id-type="pmid">26265105</pub-id></mixed-citation>
      </ref>
      <ref id="cit0024">
        <label>24.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bohnen</surname>
<given-names>NI</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>. <article-title>Body-first versus brain-first biological subtyping of Parkinson’s disease</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2020</year>;<volume>143</volume>(<issue>10</issue>):<fpage>2871</fpage>–<lpage>2873</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awaa293</pub-id><pub-id pub-id-type="pmid">33103732</pub-id></mixed-citation>
      </ref>
      <ref id="cit0025">
        <label>25.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Borghammer</surname>
<given-names>P</given-names></string-name>. <article-title>The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s Disease: explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline</article-title>. <source><italic toggle="yes">JPD</italic></source>. <year>2021</year>;<volume>11</volume>(<issue>2</issue>):<fpage>455</fpage>–<lpage>474</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JPD-202481</pub-id><pub-id pub-id-type="pmid">33682732</pub-id></mixed-citation>
      </ref>
      <ref id="cit0026">
        <label>26.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Oltra</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Uribe</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Segura</surname>
<given-names>B</given-names></string-name>, et al. <article-title>Brain atrophy pattern in de novo Parkinson’s disease with probable RBD associated with cognitive impairment</article-title>. <source><italic toggle="yes">npj Parkinsons Dis</italic></source>. <year>2022</year>;<volume>8</volume>(<issue>1</issue>):<fpage>60</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41531-022-00326-7</pub-id><pub-id pub-id-type="pmid">35610256</pub-id></mixed-citation>
      </ref>
      <ref id="cit0027">
        <label>27.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Riboldi</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Russo</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Pan</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Watkins</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kang</surname>
<given-names>UJ</given-names></string-name>. <article-title>Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson’s disease phenotypes</article-title>. <source><italic toggle="yes">npj Parkinsons Dis</italic></source>. <year>2022</year>;<volume>8</volume>(<issue>1</issue>):<fpage>110</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41531-022-00373-0</pub-id><pub-id pub-id-type="pmid">36042235</pub-id></mixed-citation>
      </ref>
      <ref id="cit0028">
        <label>28.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fereshtehnejad</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Romenets</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Anang</surname>
<given-names>JBM</given-names></string-name>, <string-name><surname>Latreille</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>. <article-title>New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: a Prospective Cohort Comparison With Other Phenotypes</article-title>. <source><italic toggle="yes">JAMA Neurol</italic></source>. <year>2015</year>;<volume>72</volume>(<issue>8</issue>):<fpage>863</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2015.0703</pub-id><pub-id pub-id-type="pmid">26076039</pub-id></mixed-citation>
      </ref>
      <ref id="cit0029">
        <label>29.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fereshtehnejad</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>. <article-title>Subtypes of Parkinson’s Disease: what Do They Tell Us About Disease Progression?</article-title>
<source><italic toggle="yes">Curr Neurol Neurosci Rep</italic></source>. <year>2017</year>;<volume>17</volume>(<issue>4</issue>). doi:<pub-id pub-id-type="doi">10.1007/s11910-017-0738-x</pub-id></mixed-citation>
      </ref>
      <ref id="cit0030">
        <label>30.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zhang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Högl</surname>
<given-names>B</given-names></string-name>, et al. <article-title>Risk Factors for Phenoconversion in Rapid Eye Movement Sleep Behavior Disorder</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2022</year>;<volume>91</volume>(<issue>3</issue>):<fpage>404</fpage>–<lpage>416</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.26298</pub-id><pub-id pub-id-type="pmid">34981563</pub-id></mixed-citation>
      </ref>
      <ref id="cit0031">
        <label>31.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Schenck</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Boeve</surname>
<given-names>BF</given-names></string-name>, <string-name><surname>Mahowald</surname>
<given-names>MW</given-names></string-name>. <article-title>Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2013</year>;<volume>14</volume>(<issue>8</issue>):<fpage>744</fpage>–<lpage>748</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2012.10.009</pub-id><pub-id pub-id-type="pmid">23347909</pub-id></mixed-citation>
      </ref>
      <ref id="cit0032">
        <label>32.</label>
        <mixed-citation publication-type="journal"><string-name><surname>de Natale</surname>
<given-names>ER</given-names></string-name>, <string-name><surname>Wilson</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Politis</surname>
<given-names>M</given-names></string-name>. <article-title>Predictors of RBD progression and conversion to synucleinopathies</article-title>. <source><italic toggle="yes">Curr Neurol Neurosci Rep</italic></source>. <year>2022</year>;<volume>22</volume>(<issue>2</issue>):<fpage>93</fpage>–<lpage>104</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11910-022-01171-0</pub-id><pub-id pub-id-type="pmid">35274191</pub-id></mixed-citation>
      </ref>
      <ref id="cit0033">
        <label>33.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Miglis</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Adler</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Antelmi</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder</article-title>. <source><italic toggle="yes">Lancet Neurol</italic></source>. <year>2021</year>;<volume>20</volume>(<issue>8</issue>):<fpage>671</fpage>–<lpage>684</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(21)00176-9</pub-id><pub-id pub-id-type="pmid">34302789</pub-id></mixed-citation>
      </ref>
      <ref id="cit0034">
        <label>34.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2019</year>;<volume>142</volume>(<issue>3</issue>):<fpage>744</fpage>–<lpage>759</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awz030</pub-id><pub-id pub-id-type="pmid">30789229</pub-id></mixed-citation>
      </ref>
      <ref id="cit0035">
        <label>35.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fereshtehnejad</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Yao</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pelletier</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>. <article-title>Evolution of prodromal Parkinson’s disease and dementia with Lewy bodies: a prospective study</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2019</year>;<volume>142</volume>(<issue>7</issue>):<fpage>2051</fpage>–<lpage>2067</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awz111</pub-id><pub-id pub-id-type="pmid">31111143</pub-id></mixed-citation>
      </ref>
      <ref id="cit0036">
        <label>36.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Del Din</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yarnall</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Barber</surname>
<given-names>TR</given-names></string-name>, et al. <article-title>Continuous Real-World Gait Monitoring in Idiopathic REM Sleep Behavior Disorder</article-title>. <source><italic toggle="yes">J Parkinsons Dis</italic></source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>283</fpage>–<lpage>299</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JPD-191773</pub-id><pub-id pub-id-type="pmid">31771071</pub-id></mixed-citation>
      </ref>
      <ref id="cit0037">
        <label>37.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Arora</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Baig</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Lo</surname>
<given-names>C</given-names></string-name>, et al. <article-title>Smartphone motor testing to distinguish idiopathic REM sleep behavior disorder, controls, and PD</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2018</year>;<volume>91</volume>(<issue>16</issue>):<fpage>e1528</fpage>–<lpage>e1538</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000006366</pub-id><pub-id pub-id-type="pmid">30232246</pub-id></mixed-citation>
      </ref>
      <ref id="cit0038">
        <label>38.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hanuška</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rusz</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Bezdicek</surname>
<given-names>O</given-names></string-name>, et al. <article-title>Eye movements in idiopathic rapid eye movement sleep behaviour disorder: high antisaccade error rate reflects prefrontal cortex dysfunction</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2019</year>;<volume>28</volume>(<issue>5</issue>):<fpage>e12742</fpage>. doi:<pub-id pub-id-type="doi">10.1111/jsr.12742</pub-id><pub-id pub-id-type="pmid">30047173</pub-id></mixed-citation>
      </ref>
      <ref id="cit0039">
        <label>39.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Krupička</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Krýže</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Neťuková</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Instrumental analysis of finger tapping reveals a novel early biomarker of parkinsonism in idiopathic rapid eye movement sleep behaviour disorder</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2020</year>;<volume>75</volume>:<fpage>45</fpage>–<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2020.07.019</pub-id><pub-id pub-id-type="pmid">32853917</pub-id></mixed-citation>
      </ref>
      <ref id="cit0040">
        <label>40.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Berg</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Adler</surname>
<given-names>CH</given-names></string-name>, et al. <article-title>MDS research criteria for prodromal Parkinson’s disease</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2015</year>;<volume>30</volume>(<issue>12</issue>):<fpage>1600</fpage>–<lpage>1611</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.26431</pub-id><pub-id pub-id-type="pmid">26474317</pub-id></mixed-citation>
      </ref>
      <ref id="cit0041">
        <label>41.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Marrero-González</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Serradell</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gaig</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Santamaria</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Vilaseca</surname>
<given-names>I</given-names></string-name>. <article-title>Significance of hyposmia in isolated REM sleep behavior disorder</article-title>. <source><italic toggle="yes">J Neurol</italic></source>. <year>2021</year>;<volume>268</volume>(<issue>3</issue>):<fpage>963</fpage>–<lpage>966</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00415-020-10229-3</pub-id><pub-id pub-id-type="pmid">32968939</pub-id></mixed-citation>
      </ref>
      <ref id="cit0042">
        <label>42.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Miyamoto</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Miyamoto</surname>
<given-names>M</given-names></string-name>. <article-title>Odor identification predicts the transition of patients with isolated RBD: a retrospective study</article-title>. <source><italic toggle="yes">Ann Clin Transl Neurol</italic></source>. <year>2022</year>;<volume>9</volume>(<issue>8</issue>):<fpage>1177</fpage>–<lpage>1185</lpage>. doi:<pub-id pub-id-type="doi">10.1002/acn3.51615</pub-id><pub-id pub-id-type="pmid">35767550</pub-id></mixed-citation>
      </ref>
      <ref id="cit0043">
        <label>43.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Vendette</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Desjardins</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>JY</given-names></string-name>. <article-title>Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2011</year>;<volume>69</volume>(<issue>5</issue>):<fpage>811</fpage>–<lpage>818</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.22282</pub-id><pub-id pub-id-type="pmid">21246603</pub-id></mixed-citation>
      </ref>
      <ref id="cit0044">
        <label>44.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Mao</surname>
<given-names>W</given-names></string-name>, et al. <article-title>Visual dysfunction in patients with idiopathic rapid eye movement sleep behavior disorder</article-title>. <source><italic toggle="yes">Neurosci Lett</italic></source>. <year>2019</year>;<volume>709</volume>:<fpage>134360</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neulet.2019.134360</pub-id><pub-id pub-id-type="pmid">31269466</pub-id></mixed-citation>
      </ref>
      <ref id="cit0045">
        <label>45.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Yang</surname>
<given-names>ZJ</given-names></string-name>, <string-name><surname>Wei</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Mao</surname>
<given-names>CJ</given-names></string-name>, et al. <article-title>Retinal nerve fiber layer thinning: a window into rapid eye movement sleep behavior disorders in Parkinson’s disease</article-title>. <source><italic toggle="yes">Sleep Breath</italic></source>. <year>2016</year>;<volume>20</volume>(<issue>4</issue>):<fpage>1285</fpage>–<lpage>1292</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11325-016-1366-4</pub-id><pub-id pub-id-type="pmid">27259748</pub-id></mixed-citation>
      </ref>
      <ref id="cit0046">
        <label>46.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ferini-Strambi</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Oertel</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case–control study</article-title>. <source><italic toggle="yes">J Neurol</italic></source>. <year>2014</year>;<volume>261</volume>(<issue>6</issue>):<fpage>1112</fpage>–<lpage>1118</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00415-014-7317-8</pub-id><pub-id pub-id-type="pmid">24687894</pub-id></mixed-citation>
      </ref>
      <ref id="cit0047">
        <label>47.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zitser</surname>
<given-names>J</given-names></string-name>, <string-name><surname>During</surname>
<given-names>EH</given-names></string-name>, <string-name><surname>Chiaro</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Miglis</surname>
<given-names>MG</given-names></string-name>. <article-title>Autonomic impairment as a potential biomarker in idiopathic REM-sleep-behavior disorder</article-title>. <source><italic toggle="yes">Autonomic Neurosci</italic></source>. <year>2019</year>;<volume>220</volume>:<fpage>102553</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.autneu.2019.05.005</pub-id></mixed-citation>
      </ref>
      <ref id="cit0048">
        <label>48.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Lanfranchi</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Blais</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>JY</given-names></string-name>. <article-title>Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2010</year>;<volume>25</volume>(<issue>14</issue>):<fpage>2304</fpage>–<lpage>2310</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.23347</pub-id><pub-id pub-id-type="pmid">20669316</pub-id></mixed-citation>
      </ref>
      <ref id="cit0049">
        <label>49.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Yang</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Choi</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>MH</given-names></string-name>, et al. <article-title>Association of heart rate variability with REM sleep without atonia in idiopathic REM sleep behavior disorder</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2021</year>;<volume>17</volume>(<issue>3</issue>):<fpage>461</fpage>–<lpage>469</lpage>. doi:<pub-id pub-id-type="doi">10.5664/JCSM.8934</pub-id><pub-id pub-id-type="pmid">33112228</pub-id></mixed-citation>
      </ref>
      <ref id="cit0050">
        <label>50.</label>
        <mixed-citation publication-type="journal"><string-name><surname>McCarter</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Gehrking</surname>
<given-names>TL</given-names></string-name>, <string-name><surname>St Louis</surname>
<given-names>EK</given-names></string-name>, et al. <article-title>Autonomic dysfunction and phenoconversion in idiopathic REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Clin Auton Res</italic></source>. <year>2020</year>;<volume>30</volume>(<issue>3</issue>):<fpage>207</fpage>–<lpage>213</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10286-020-00674-5</pub-id><pub-id pub-id-type="pmid">32193800</pub-id></mixed-citation>
      </ref>
      <ref id="cit0051">
        <label>51.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bauckneht</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Chincarini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>De Carli</surname>
<given-names>F</given-names></string-name>, et al. <article-title>Presynaptic dopaminergic neuroimaging in REM sleep behavior disorder: a systematic review and meta-analysis</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2018</year>;<volume>41</volume>:<fpage>266</fpage>–<lpage>274</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2018.04.001</pub-id><pub-id pub-id-type="pmid">29784534</pub-id></mixed-citation>
      </ref>
      <ref id="cit0052">
        <label>52.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Santamaría</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Valldeoriola</surname>
<given-names>F</given-names></string-name>, et al. <article-title>Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2017</year>;<volume>82</volume>(<issue>3</issue>):<fpage>419</fpage>–<lpage>428</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.25026</pub-id><pub-id pub-id-type="pmid">28833467</pub-id></mixed-citation>
      </ref>
      <ref id="cit0053">
        <label>53.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>Q</given-names></string-name>, et al. <article-title>Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2017</year>;<volume>88</volume>(<issue>16</issue>):<fpage>1493</fpage>–<lpage>1500</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000003838</pub-id><pub-id pub-id-type="pmid">28330956</pub-id></mixed-citation>
      </ref>
      <ref id="cit0054">
        <label>54.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chahine</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Brumm</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Caspell-Garcia</surname>
<given-names>C</given-names></string-name>, et al. <article-title>Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Ann Clin Transl Neurol</italic></source>. <year>2021</year>;<volume>8</volume>(<issue>1</issue>):<fpage>201</fpage>–<lpage>212</lpage>. doi:<pub-id pub-id-type="doi">10.1002/acn3.51269</pub-id><pub-id pub-id-type="pmid">33321002</pub-id></mixed-citation>
      </ref>
      <ref id="cit0055">
        <label>55.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Arnaldi</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Chincarini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>MT</given-names></string-name>, et al. <article-title>Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2021</year>;<volume>144</volume>(<issue>1</issue>):<fpage>278</fpage>–<lpage>287</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awaa365</pub-id><pub-id pub-id-type="pmid">33348363</pub-id></mixed-citation>
      </ref>
      <ref id="cit0056">
        <label>56.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Arnaldi</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Famà</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Girtler</surname>
<given-names>N</given-names></string-name>, et al. <article-title>Rapid eye movement sleep behavior disorder: a proof-of-concept neuroprotection study for prodromal synucleinopathies</article-title>. <source><italic toggle="yes">Eur J Neurol</italic></source>. <year>2021</year>;<volume>28</volume>(<issue>4</issue>):<fpage>1210</fpage>–<lpage>1217</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ene.14664</pub-id><pub-id pub-id-type="pmid">33275819</pub-id></mixed-citation>
      </ref>
      <ref id="cit0057">
        <label>57.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dang-Vu</surname>
<given-names>TT</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Vendette</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Soucy</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>. <article-title>Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2012</year>;<volume>79</volume>(<issue>24</issue>):<fpage>2302</fpage>–<lpage>2306</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0b013e318278b658</pub-id><pub-id pub-id-type="pmid">23115214</pub-id></mixed-citation>
      </ref>
      <ref id="cit0058">
        <label>58.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Heller</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Brcina</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Dogan</surname>
<given-names>I</given-names></string-name>, et al. <article-title>Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) – a systematic review on potential biomarkers for neurodegeneration</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2017</year>;<volume>34</volume>:<fpage>23</fpage>–<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2016.06.006</pub-id><pub-id pub-id-type="pmid">27542516</pub-id></mixed-citation>
      </ref>
      <ref id="cit0059">
        <label>59.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Campabadal</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Segura</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Junque</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>. <article-title>Structural and functional magnetic resonance imaging in isolated REM sleep behavior disorder: a systematic review of studies using neuroimaging software</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2021</year>;<volume>59</volume>:<fpage>101495</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2021.101495</pub-id><pub-id pub-id-type="pmid">33979733</pub-id></mixed-citation>
      </ref>
      <ref id="cit0060">
        <label>60.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ota</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kanel</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Bohnen</surname>
<given-names>N</given-names></string-name>. <article-title>Imaging of sleep disorders in pre-Parkinsonian syndromes</article-title>. <source><italic toggle="yes">Curr Opin Neurol</italic></source>. <year>2022</year>;<volume>35</volume>(<issue>4</issue>):<fpage>443</fpage>–<lpage>452</lpage>. doi:<pub-id pub-id-type="doi">10.1097/WCO.0000000000001084</pub-id><pub-id pub-id-type="pmid">35788559</pub-id></mixed-citation>
      </ref>
      <ref id="cit0061">
        <label>61.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Shi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sheng</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Stewart</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Zabetian</surname>
<given-names>CP</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>. <article-title>New windows into the brain: central nervous system-derived extracellular vesicles in blood</article-title>. <source><italic toggle="yes">Prog Neurobiol</italic></source>. <year>2019</year>;<volume>175</volume>:<fpage>96</fpage>–<lpage>106</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pneurobio.2019.01.005</pub-id><pub-id pub-id-type="pmid">30685501</pub-id></mixed-citation>
      </ref>
      <ref id="cit0062">
        <label>62.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kluge</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bunk</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Schaeffer</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Detection of neuron-derived pathological α-synuclein in blood</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2022</year>;<volume>145</volume>(<issue>9</issue>):<fpage>3058</fpage>–<lpage>3071</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awac115</pub-id><pub-id pub-id-type="pmid">35722765</pub-id></mixed-citation>
      </ref>
      <ref id="cit0063">
        <label>63.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Stefani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Holzknecht</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2021</year>;<volume>144</volume>(<issue>4</issue>):<fpage>1118</fpage>–<lpage>1126</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awab005</pub-id><pub-id pub-id-type="pmid">33855335</pub-id></mixed-citation>
      </ref>
      <ref id="cit0064">
        <label>64.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zitser</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gibbons</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Miglis</surname>
<given-names>MG</given-names></string-name>. <article-title>The role of tissue biopsy as a biomarker in REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2020</year>;<volume>51</volume>:<fpage>101283</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2020.101283</pub-id><pub-id pub-id-type="pmid">32187564</pub-id></mixed-citation>
      </ref>
      <ref id="cit0065">
        <label>65.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Fairfoul</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ayudhaya</surname>
<given-names>ACN</given-names></string-name>, et al. <article-title>Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study</article-title>. <source><italic toggle="yes">Lancet Neurol</italic></source>. <year>2021</year>;<volume>20</volume>(<issue>3</issue>):<fpage>203</fpage>–<lpage>212</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(20)30449-X</pub-id><pub-id pub-id-type="pmid">33609478</pub-id></mixed-citation>
      </ref>
      <ref id="cit0066">
        <label>66.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Thaler</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bregman</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Gurevich</surname>
<given-names>T</given-names></string-name>, et al. <article-title>Parkinson’s disease phenotype is influenced by the severity of the mutations in the GBA gene</article-title>. <source><italic toggle="yes">Parkinsonism Relat Disord</italic></source>. <year>2018</year>;<volume>55</volume>:<fpage>45</fpage>–<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.parkreldis.2018.05.009</pub-id><pub-id pub-id-type="pmid">29784561</pub-id></mixed-citation>
      </ref>
      <ref id="cit0067">
        <label>67.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Krohn</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ruskey</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Rudakou</surname>
<given-names>U</given-names></string-name>, et al. <article-title>GBA variants in REM sleep behavior disorder: a multicenter study</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2020</year>;<volume>95</volume>(<issue>8</issue>):<fpage>e1008</fpage>–<lpage>e1016</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000010042</pub-id><pub-id pub-id-type="pmid">32591474</pub-id></mixed-citation>
      </ref>
      <ref id="cit0068">
        <label>68.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Honeycutt</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, et al. <article-title>Glucocerebrosidase mutations and phenoconversion of REM sleep behavior disorder to parkinsonism and dementia</article-title>. <source><italic toggle="yes">Parkinsonism Relat Disord</italic></source>. <year>2019</year>;<volume>65</volume>:<fpage>230</fpage>–<lpage>233</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.parkreldis.2019.04.016</pub-id><pub-id pub-id-type="pmid">31076265</pub-id></mixed-citation>
      </ref>
      <ref id="cit0069">
        <label>69.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Krohn</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>RYJ</given-names></string-name>, <string-name><surname>Heilbron</surname>
<given-names>K</given-names></string-name>, et al. <article-title>Fine‐Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2020</year>;<volume>87</volume>(<issue>4</issue>):<fpage>584</fpage>–<lpage>598</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.25687</pub-id><pub-id pub-id-type="pmid">31976583</pub-id></mixed-citation>
      </ref>
      <ref id="cit0070">
        <label>70.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ye</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Predictors of Conversion to α-Synucleinopathy Diseases in Idiopathic Rapid Eye Movement Sleep Behavior Disorder</article-title>. <source><italic toggle="yes">J Parkinsons Dis</italic></source>. <year>2020</year>;<volume>10</volume>(<issue>4</issue>):<fpage>1443</fpage>–<lpage>1455</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JPD-202243</pub-id><pub-id pub-id-type="pmid">32986685</pub-id></mixed-citation>
      </ref>
      <ref id="cit0071">
        <label>71.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Terzaghi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Toscano</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Casoni</surname>
<given-names>F</given-names></string-name>, et al. <article-title>Assessment of cognitive profile as a prodromal marker of the evolution of REM sleep Behavior Disorder</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2019</year>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsz103</pub-id></mixed-citation>
      </ref>
      <ref id="cit0072">
        <label>72.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Vendette</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gosselin</surname>
<given-names>N</given-names></string-name>, et al. <article-title>Brain perfusion anomalies in rapid eye movement sleep behavior disorder with mild cognitive impairment</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2012</year>;<volume>27</volume>(<issue>10</issue>):<fpage>1255</fpage>–<lpage>1261</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.25034</pub-id><pub-id pub-id-type="pmid">22791632</pub-id></mixed-citation>
      </ref>
      <ref id="cit0073">
        <label>73.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jozwiak</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, et al. <article-title>REM Sleep Behavior Disorder and Cognitive Impairment in Parkinson’s Disease</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2017</year>;<volume>40</volume>:<fpage>8</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsx101</pub-id></mixed-citation>
      </ref>
      <ref id="cit0074">
        <label>74.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Marchand</surname>
<given-names>DG</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Rahayel</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>. <article-title>Detecting the Cognitive Prodrome of Dementia with Lewy Bodies: a Prospective Study of REM Sleep Behavior Disorder</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2017</year>;<volume>40</volume>:<fpage>1</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsw014</pub-id></mixed-citation>
      </ref>
      <ref id="cit0075">
        <label>75.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Vendette</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, et al. <article-title>Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson’s disease</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2009</year>;<volume>66</volume>(<issue>1</issue>):<fpage>39</fpage>–<lpage>47</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.21680</pub-id><pub-id pub-id-type="pmid">19670440</pub-id></mixed-citation>
      </ref>
      <ref id="cit0076">
        <label>76.</label>
        <mixed-citation publication-type="journal"><string-name><surname>McCarter</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Tabatabai</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Jong</surname>
<given-names>HY</given-names></string-name>, et al. <article-title>REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2020</year>;<volume>94</volume>(<issue>1</issue>):<fpage>e15</fpage>–<lpage>e29</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000008694</pub-id><pub-id pub-id-type="pmid">31831602</pub-id></mixed-citation>
      </ref>
      <ref id="cit0077">
        <label>77.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Rahayel</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Cortical and subcortical gray matter bases of cognitive deficits in REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2018</year>;<volume>90</volume>(<issue>20</issue>):<fpage>e1759</fpage>–<lpage>e1770</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000005523</pub-id><pub-id pub-id-type="pmid">29669906</pub-id></mixed-citation>
      </ref>
      <ref id="cit0078">
        <label>78.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Rahayel</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, et al. <article-title>A Prodromal Brain-Clinical Pattern of Cognition in Synucleinopathies</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2021</year>;<volume>89</volume>(<issue>2</issue>):<fpage>341</fpage>–<lpage>357</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.25962</pub-id><pub-id pub-id-type="pmid">33217037</pub-id></mixed-citation>
      </ref>
      <ref id="cit0079">
        <label>79.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Rémillard-Pelchat</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Rahayel</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gaubert</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Comprehensive Analysis of Brain Volume in REM Sleep Behavior Disorder with Mild Cognitive Impairment</article-title>. <source><italic toggle="yes">J Parkinsons Dis</italic></source>. <year>2022</year>;<volume>12</volume>(<issue>1</issue>):<fpage>229</fpage>–<lpage>241</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JPD-212691</pub-id><pub-id pub-id-type="pmid">34690149</pub-id></mixed-citation>
      </ref>
      <ref id="cit0080">
        <label>80.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hogl</surname>
<given-names>B</given-names></string-name>, et al. <article-title>Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2015</year>;<volume>77</volume>(<issue>5</issue>):<fpage>830</fpage>–<lpage>839</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.24385</pub-id><pub-id pub-id-type="pmid">25767079</pub-id></mixed-citation>
      </ref>
      <ref id="cit0081">
        <label>81.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Génier Marchand</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Escudier</surname>
<given-names>F</given-names></string-name>, et al. <article-title>How does dementia with Lewy bodies start? Prodromal cognitive changes in REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2018</year>;<volume>83</volume>(<issue>5</issue>):<fpage>1016</fpage>–<lpage>1026</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.25239</pub-id><pub-id pub-id-type="pmid">29665124</pub-id></mixed-citation>
      </ref>
      <ref id="cit0082">
        <label>82.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Génier Marchand</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Rahayel</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>. <article-title>Detecting the Cognitive Prodrome of Dementia with Lewy Bodies: a Prospective Study of REM Sleep Behavior Disorder</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2017</year>;<volume>40</volume>:<fpage>1</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsw014</pub-id></mixed-citation>
      </ref>
      <ref id="cit0083">
        <label>83.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Heinzel</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Berg</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Gasser</surname>
<given-names>T</given-names></string-name>, et al. <article-title>Update of the MDS research criteria for prodromal Parkinson’s disease</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2019</year>;<volume>34</volume>(<issue>10</issue>):<fpage>1464</fpage>–<lpage>1470</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.27802</pub-id><pub-id pub-id-type="pmid">31412427</pub-id></mixed-citation>
      </ref>
      <ref id="cit0084">
        <label>84.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Bertrand</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Génier Marchand</surname>
<given-names>D</given-names></string-name>. <article-title>Cognition in rapid eye movement sleep behavior disorder</article-title>. <source><italic toggle="yes">Front Neurol</italic></source>. <year>2012</year>;<volume>3</volume>:<fpage>82</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2012.00082</pub-id><pub-id pub-id-type="pmid">22629254</pub-id></mixed-citation>
      </ref>
      <ref id="cit0085">
        <label>85.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ferini-Strambi</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Fasiello</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Sforza</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Salsone</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Galbiati</surname>
<given-names>A</given-names></string-name>. <article-title>Neuropsychological, electrophysiological, and neuroimaging biomarkers for REM behavior disorder</article-title>. <source><italic toggle="yes">Expert Rev Neurother</italic></source>. <year>2019</year>;<volume>19</volume>(<issue>11</issue>):<fpage>1069</fpage>–<lpage>1087</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14737175.2019.1640603</pub-id><pub-id pub-id-type="pmid">31277555</pub-id></mixed-citation>
      </ref>
      <ref id="cit0086">
        <label>86.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Figorilli</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lanza</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Congiu</surname>
<given-names>P</given-names></string-name>, et al. <article-title>Neurophysiological Aspects of REM Sleep Behavior Disorder (RBD): a Narrative Review</article-title>. <source><italic toggle="yes">Brain Sci</italic></source>. <year>2021</year>;<volume>11</volume>(<issue>12</issue>):<fpage>1588</fpage>. doi:<pub-id pub-id-type="doi">10.3390/brainsci11121588</pub-id><pub-id pub-id-type="pmid">34942893</pub-id></mixed-citation>
      </ref>
      <ref id="cit0087">
        <label>87.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Valomon</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Riedner</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>Jones</surname>
<given-names>SG</given-names></string-name>, et al. <article-title>A high-density electroencephalography study reveals abnormal sleep homeostasis in patients with rapid eye movement sleep behavior disorder</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>4758</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-021-83980-w</pub-id><pub-id pub-id-type="pmid">33637812</pub-id></mixed-citation>
      </ref>
      <ref id="cit0088">
        <label>88.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ferri</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Rundo</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Silvani</surname>
<given-names>A</given-names></string-name>, et al. <article-title>REM Sleep EEG Instability in REM Sleep Behavior Disorder and Clonazepam Effects</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2017</year>;<volume>40</volume>:<fpage>8</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsx080</pub-id></mixed-citation>
      </ref>
      <ref id="cit0089">
        <label>89.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ferri</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Zucconi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Marelli</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Plazzi</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Schenck</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Ferini-Strambi</surname>
<given-names>L</given-names></string-name>. <article-title>Effects of long-term use of clonazepam on nonrapid eye movement sleep patterns in rapid eye movement sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2013</year>;<volume>14</volume>(<issue>5</issue>):<fpage>399</fpage>–<lpage>406</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2013.01.007</pub-id><pub-id pub-id-type="pmid">23490738</pub-id></mixed-citation>
      </ref>
      <ref id="cit0090">
        <label>90.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Shin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>WW</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Jeon</surname>
<given-names>B</given-names></string-name>. <article-title>Clonazepam for probable REM sleep behavior disorder in Parkinson’s disease: a randomized placebo-controlled trial</article-title>. <source><italic toggle="yes">J Neurol Sci</italic></source>. <year>2019</year>;<volume>401</volume>:<fpage>81</fpage>–<lpage>86</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jns.2019.04.029</pub-id><pub-id pub-id-type="pmid">31035190</pub-id></mixed-citation>
      </ref>
      <ref id="cit0091">
        <label>91.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hadi</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Agah</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Tavanbakhsh</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson’s disease and sleep disorders: a randomized, double-blind trial</article-title>. <source><italic toggle="yes">Neurol Sci</italic></source>. <year>2022</year>;<volume>43</volume>(<issue>10</issue>):<fpage>6141</fpage>–<lpage>6148</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10072-022-06188-4</pub-id><pub-id pub-id-type="pmid">35660990</pub-id></mixed-citation>
      </ref>
      <ref id="cit0092">
        <label>92.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Yan</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Pharmacological Interventions for REM Sleep Behavior Disorder in Parkinson’s Disease: a Systematic Review</article-title>. <source><italic toggle="yes">Front Aging Neurosci</italic></source>. <year>2021</year>;<volume>13</volume>:<fpage>709878</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2021.709878</pub-id><pub-id pub-id-type="pmid">34483882</pub-id></mixed-citation>
      </ref>
      <ref id="cit0093">
        <label>93.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Que</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Zheng</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>Z</given-names></string-name>, et al. <article-title>The treatment efficacy of pharmacotherapies for rapid eye movement sleep behavior disorder with polysomnography evaluation: a systematic review and meta-analysis</article-title>. <source><italic toggle="yes">Heliyon</italic></source>. <year>2022</year>;<volume>8</volume>(<issue>11</issue>):<fpage>e11425</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e11425</pub-id><pub-id pub-id-type="pmid">36387478</pub-id></mixed-citation>
      </ref>
      <ref id="cit0094">
        <label>94.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Brooks</surname>
<given-names>PL</given-names></string-name>, <string-name><surname>Peever</surname>
<given-names>JH</given-names></string-name>. <article-title>Impaired GABA and glycine transmission triggers cardinal features of rapid eye movement sleep behavior disorder in mice</article-title>. <source><italic toggle="yes">J Neurosci</italic></source>. <year>2011</year>;<volume>31</volume>(<issue>19</issue>):<fpage>7111</fpage>–<lpage>7121</lpage>. doi:<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0347-11.2011</pub-id><pub-id pub-id-type="pmid">21562273</pub-id></mixed-citation>
      </ref>
      <ref id="cit0095">
        <label>95.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Parrino</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ferri</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Bruni</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Terzano</surname>
<given-names>MG</given-names></string-name>. <article-title>Cyclic alternating pattern (CAP): the marker of sleep instability</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2012</year>;<volume>16</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>45</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2011.02.003</pub-id><pub-id pub-id-type="pmid">21616693</pub-id></mixed-citation>
      </ref>
      <ref id="cit0096">
        <label>96.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kutlu</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Işeri</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Selekler</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Benbir</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Karadeniz</surname>
<given-names>D</given-names></string-name>. <article-title>Cyclic alternating pattern analysis in REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep and Breathing</italic></source>. <year>2013</year>;<volume>17</volume>(<issue>1</issue>):<fpage>209</fpage>–<lpage>215</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11325-012-0675-5</pub-id><pub-id pub-id-type="pmid">22367462</pub-id></mixed-citation>
      </ref>
      <ref id="cit0097">
        <label>97.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Melpignano</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Parrino</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Santamaria</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Isolated rapid eye movement sleep behavior disorder and cyclic alternating pattern: is sleep microstructure a predictive parameter of neurodegeneration?</article-title>
<source><italic toggle="yes">Sleep</italic></source>. <year>2019</year>;<volume>42</volume>(<issue>10</issue>):<fpage>zsz142</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsz142</pub-id><pub-id pub-id-type="pmid">31323084</pub-id></mixed-citation>
      </ref>
      <ref id="cit0098">
        <label>98.</label>
        <mixed-citation publication-type="journal"><string-name><surname>O’Reilly</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Godin</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Nielsen</surname>
<given-names>T</given-names></string-name>. <article-title>REM sleep behaviour disorder is associated with lower fast and higher slow sleep spindle densities</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2015</year>;<volume>24</volume>(<issue>6</issue>):<fpage>593</fpage>–<lpage>601</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jsr.12309</pub-id><pub-id pub-id-type="pmid">26041532</pub-id></mixed-citation>
      </ref>
      <ref id="cit0099">
        <label>99.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Christensen</surname>
<given-names>JAE</given-names></string-name>, <string-name><surname>Kempfner</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zoetmulder</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Decreased sleep spindle density in patients with idiopathic REM sleep behavior disorder and patients with Parkinson’s disease</article-title>. <source><italic toggle="yes">Clin Neurophysiol</italic></source>. <year>2014</year>;<volume>125</volume>(<issue>3</issue>):<fpage>512</fpage>–<lpage>519</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clinph.2013.08.013</pub-id><pub-id pub-id-type="pmid">24125856</pub-id></mixed-citation>
      </ref>
      <ref id="cit0100">
        <label>100.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ruffini</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ibañez</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Castellano</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Deep Learning With EEG Spectrograms in Rapid Eye Movement Behavior Disorder</article-title>. <source><italic toggle="yes">Front Neurol</italic></source>. <year>2019</year>;<volume>10</volume>:<fpage>806</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2019.00806</pub-id><pub-id pub-id-type="pmid">31417485</pub-id></mixed-citation>
      </ref>
      <ref id="cit0101">
        <label>101.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gong</surname>
<given-names>S-Y</given-names></string-name>, <string-name><surname>Shen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Gu</surname>
<given-names>H-Y</given-names></string-name>, et al. <article-title>Generalized EEG Slowing Across Phasic REM Sleep, Not Subjective RBD Severity, Predicts Neurodegeneration in Idiopathic RBD</article-title>. <source><italic toggle="yes">Nat Sci Sleep</italic></source>. <year>2022</year>;<volume>14</volume>:<fpage>407</fpage>–<lpage>418</lpage>. doi:<pub-id pub-id-type="doi">10.2147/NSS.S354063</pub-id><pub-id pub-id-type="pmid">35299628</pub-id></mixed-citation>
      </ref>
      <ref id="cit0102">
        <label>102.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lanza</surname>
<given-names>G</given-names></string-name>, <string-name><surname>DelRosso</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Ferri</surname>
<given-names>R</given-names></string-name>. <article-title>Sleep and homeostatic control of plasticity</article-title>. <source><italic toggle="yes">Handb Clin Neurol</italic></source>. <year>2022</year>;<volume>184</volume>:<fpage>53</fpage>–<lpage>72</lpage>. doi:<pub-id pub-id-type="doi">10.1016/B978-0-12-819410-2.00004-7</pub-id><pub-id pub-id-type="pmid">35034758</pub-id></mixed-citation>
      </ref>
      <ref id="cit0103">
        <label>103.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fisicaro</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Lanza</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Cantone</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Clinical and Electrophysiological Hints to TMS in De Novo Patients with Parkinson’s Disease and Progressive Supranuclear Palsy</article-title>. <source><italic toggle="yes">J Pers Med</italic></source>. <year>2020</year>;<volume>10</volume>(<issue>4</issue>):<fpage>E274</fpage>. doi:<pub-id pub-id-type="doi">10.3390/jpm10040274</pub-id></mixed-citation>
      </ref>
      <ref id="cit0104">
        <label>104.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Cantone</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lanza</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ranieri</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Opie</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Terranova</surname>
<given-names>C</given-names></string-name>. <article-title>Editorial: non-invasive Brain Stimulation in the Study and Modulation of Metaplasticity in Neurological Disorders</article-title>. <source><italic toggle="yes">Front Neurol</italic></source>. <year>2021</year>;<volume>12</volume>:<fpage>721906</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2021.721906</pub-id><pub-id pub-id-type="pmid">34276553</pub-id></mixed-citation>
      </ref>
      <ref id="cit0105">
        <label>105.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Di Lazzaro</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Bella</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Benussi</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia</article-title>. <source><italic toggle="yes">Clin Neurophysiol</italic></source>. <year>2021</year>;<volume>132</volume>(<issue>10</issue>):<fpage>2568</fpage>–<lpage>2607</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clinph.2021.05.035</pub-id><pub-id pub-id-type="pmid">34482205</pub-id></mixed-citation>
      </ref>
      <ref id="cit0106">
        <label>106.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Nardone</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Bergmann</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kunz</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Cortical afferent inhibition is reduced in patients with idiopathic REM sleep behavior disorder and cognitive impairment: a TMS study</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2012</year>;<volume>13</volume>(<issue>7</issue>):<fpage>919</fpage>–<lpage>925</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2012.03.009</pub-id><pub-id pub-id-type="pmid">22726269</pub-id></mixed-citation>
      </ref>
      <ref id="cit0107">
        <label>107.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Nardone</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Bergmann</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Brigo</surname>
<given-names>F</given-names></string-name>, et al. <article-title>Functional evaluation of central cholinergic circuits in patients with Parkinson’s disease and REM sleep behavior disorder: a TMS study</article-title>. <source><italic toggle="yes">J Neural Transm</italic></source>. <year>2013</year>;<volume>120</volume>(<issue>3</issue>):<fpage>413</fpage>–<lpage>422</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00702-012-0888-6</pub-id><pub-id pub-id-type="pmid">22903350</pub-id></mixed-citation>
      </ref>
      <ref id="cit0108">
        <label>108.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lanza</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Aricò</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Lanuzza</surname>
<given-names>B</given-names></string-name>, et al. <article-title>Facilitatory/inhibitory intracortical imbalance in REM sleep behavior disorder: early electrophysiological marker of neurodegeneration?</article-title>
<source><italic toggle="yes">Sleep</italic></source>. <year>2020</year>;<volume>43</volume>(<issue>3</issue>):<fpage>zsz242</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsz242</pub-id><pub-id pub-id-type="pmid">31599326</pub-id></mixed-citation>
      </ref>
      <ref id="cit0109">
        <label>109.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Peever</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Luppi</surname>
<given-names>PH</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>. <article-title>Breakdown in REM sleep circuitry underlies REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Trends Neurosci</italic></source>. <year>2014</year>;<volume>37</volume>(<issue>5</issue>):<fpage>279</fpage>–<lpage>288</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tins.2014.02.009</pub-id><pub-id pub-id-type="pmid">24673896</pub-id></mixed-citation>
      </ref>
      <ref id="cit0110">
        <label>110.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lanza</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Cosentino</surname>
<given-names>FII</given-names></string-name>, <string-name><surname>Lanuzza</surname>
<given-names>B</given-names></string-name>, et al. <article-title>Reduced Intracortical Facilitation to TMS in Both Isolated REM Sleep Behavior Disorder (RBD) and Early Parkinson’s Disease with RBD</article-title>. <source><italic toggle="yes">J Clin Med</italic></source>. <year>2022</year>;<volume>11</volume>(<issue>9</issue>):<fpage>2291</fpage>. doi:<pub-id pub-id-type="doi">10.3390/jcm11092291</pub-id><pub-id pub-id-type="pmid">35566417</pub-id></mixed-citation>
      </ref>
      <ref id="cit0111">
        <label>111.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bhattacharya</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kamble</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Yadav</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Stezin</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pal</surname>
<given-names>PK</given-names></string-name>. <article-title>Abnormal Intracortical Functions in Parkinson’s Disease with Rapid Eye Movement Sleep Behaviour Disorder</article-title>. <source><italic toggle="yes">Can J Neurol Sci</italic></source>. <year>2022</year>;<volume>49</volume>(<issue>5</issue>):<fpage>672</fpage>–<lpage>677</lpage>. doi:<pub-id pub-id-type="doi">10.1017/cjn.2021.206</pub-id><pub-id pub-id-type="pmid">34470683</pub-id></mixed-citation>
      </ref>
      <ref id="cit0112">
        <label>112.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lanza</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Fisicaro</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Cantone</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Repetitive transcranial magnetic stimulation in primary sleep disorders</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2023</year>;<volume>67</volume>:<fpage>101735</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2022.101735</pub-id><pub-id pub-id-type="pmid">36563570</pub-id></mixed-citation>
      </ref>
      <ref id="cit0113">
        <label>113.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Magnano</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Pes</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Cabboi</surname>
<given-names>MP</given-names></string-name>, et al. <article-title>Comparison of brainstem reflex recordings and evoked potentials with clinical and MRI data to assess brainstem dysfunction in multiple sclerosis: a short-term follow-up</article-title>. <source><italic toggle="yes">Neurol Sci</italic></source>. <year>2016</year>;<volume>37</volume>(<issue>9</issue>):<fpage>1457</fpage>–<lpage>1465</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10072-016-2604-z</pub-id><pub-id pub-id-type="pmid">27177651</pub-id></mixed-citation>
      </ref>
      <ref id="cit0114">
        <label>114.</label>
        <mixed-citation publication-type="journal"><string-name><surname>de Natale</surname>
<given-names>ER</given-names></string-name>, <string-name><surname>Ginatempo</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Laccu</surname>
<given-names>I</given-names></string-name>, et al. <article-title>Vestibular Evoked Myogenic Potentials Are Abnormal in Idiopathic REM Sleep Behavior Disorder</article-title>. <source><italic toggle="yes">Front Neurol</italic></source>. <year>2018</year>;<volume>9</volume>:<fpage>911</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2018.00911</pub-id><pub-id pub-id-type="pmid">30420831</pub-id></mixed-citation>
      </ref>
      <ref id="cit0115">
        <label>115.</label>
        <mixed-citation publication-type="journal"><string-name><surname>de Natale</surname>
<given-names>ER</given-names></string-name>, <string-name><surname>Ginatempo</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Paulus</surname>
<given-names>KS</given-names></string-name>, et al. <article-title>Abnormalities of vestibular-evoked myogenic potentials in idiopathic Parkinson’s disease are associated with clinical evidence of brainstem involvement</article-title>. <source><italic toggle="yes">Neurol Sci</italic></source>. <year>2015</year>;<volume>36</volume>(<issue>6</issue>):<fpage>995</fpage>–<lpage>1001</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10072-014-2054-4</pub-id><pub-id pub-id-type="pmid">25567081</pub-id></mixed-citation>
      </ref>
      <ref id="cit0116">
        <label>116.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Puligheddu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Figorilli</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Serra</surname>
<given-names>A</given-names></string-name>, et al. <article-title>REM Sleep without atonia correlates with abnormal vestibular-evoked myogenic potentials in isolated REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2019</year>;<volume>42</volume>(<issue>9</issue>):<fpage>zsz128</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsz128</pub-id><pub-id pub-id-type="pmid">31310647</pub-id></mixed-citation>
      </ref>
      <ref id="cit0117">
        <label>117.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Xie</surname>
<given-names>WY</given-names></string-name>, <string-name><surname>Shen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>REM sleep without atonia and vestibular-evoked myogenic potentials: clinical brainstem dysfunction in early-stage Parkinson’s disease and isolated REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2022</year>;<volume>89</volume>:<fpage>122</fpage>–<lpage>129</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2021.12.004</pub-id><pub-id pub-id-type="pmid">34974306</pub-id></mixed-citation>
      </ref>
      <ref id="cit0118">
        <label>118.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Stefani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Holzknecht</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Högl</surname>
<given-names>B</given-names></string-name>. <article-title>Clinical neurophysiology of REM parasomnias</article-title>. <source><italic toggle="yes">Handb Clin Neurol</italic></source>. <year>2019</year>;<volume>161</volume>:<fpage>381</fpage>–<lpage>396</lpage>. doi:<pub-id pub-id-type="doi">10.1016/B978-0-444-64142-7.00062-X</pub-id><pub-id pub-id-type="pmid">31307615</pub-id></mixed-citation>
      </ref>
      <ref id="cit0119">
        <label>119.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Perkins</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Janzen</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bernhard</surname>
<given-names>FP</given-names></string-name>, et al. <article-title>Saccade, Pupil, and Blink Responses in Rapid Eye Movement Sleep Behavior Disorder</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2021</year>;<volume>36</volume>(<issue>7</issue>):<fpage>1720</fpage>–<lpage>1726</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.28585</pub-id><pub-id pub-id-type="pmid">33754406</pub-id></mixed-citation>
      </ref>
      <ref id="cit0120">
        <label>120.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Weise</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Pargac</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pelz</surname>
<given-names>JO</given-names></string-name>, <string-name><surname>Rumpf</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Fricke</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Classen</surname>
<given-names>J</given-names></string-name>. <article-title>Assessing blink reflex circuits by three different afferent routes in Parkinson’s disease</article-title>. <source><italic toggle="yes">Clin Neurophysiol</italic></source>. <year>2019</year>;<volume>130</volume>(<issue>4</issue>):<fpage>582</fpage>–<lpage>587</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clinph.2018.12.009</pub-id><pub-id pub-id-type="pmid">30704843</pub-id></mixed-citation>
      </ref>
      <ref id="cit0121">
        <label>121.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Aygün</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ertaş</surname>
<given-names>Fİ</given-names></string-name>, <string-name><surname>Gündüz</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Benbir Şenel</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Karadeniz</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kızıltan</surname>
<given-names>M</given-names></string-name>. <article-title>The role of pedunculopontine nucleus in isolated REM sleep behavior disorder and REM sleep without atonia</article-title>. <source><italic toggle="yes">Parkinsonism Relat Disord</italic></source>. <year>2021</year>;<volume>84</volume>:<fpage>68</fpage>–<lpage>73</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.parkreldis.2021.01.025</pub-id><pub-id pub-id-type="pmid">33571873</pub-id></mixed-citation>
      </ref>
      <ref id="cit0122">
        <label>122.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Frauscher</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Nomura</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Duerr</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Investigation of autonomic function in idiopathic REM sleep behavior disorder</article-title>. <source><italic toggle="yes">J Neurol</italic></source>. <year>2012</year>;<volume>259</volume>(<issue>6</issue>):<fpage>1056</fpage>–<lpage>1061</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00415-011-6298-0</pub-id><pub-id pub-id-type="pmid">22064976</pub-id></mixed-citation>
      </ref>
      <ref id="cit0123">
        <label>123.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Pilotto</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Romagnolo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tuazon</surname>
<given-names>JA</given-names></string-name>, et al. <article-title>Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α-synucleinopathies</article-title>. <source><italic toggle="yes">J Neurol Neurosurg Psychiatry</italic></source>. <year>2019</year>;<volume>90</volume>(<issue>11</issue>):<fpage>1257</fpage>–<lpage>1263</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jnnp-2019-320846</pub-id><pub-id pub-id-type="pmid">31142660</pub-id></mixed-citation>
      </ref>
      <ref id="cit0124">
        <label>124.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jung</surname>
<given-names>KY</given-names></string-name>, <string-name><surname>Cho</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Ko</surname>
<given-names>D</given-names></string-name>, et al. <article-title>Increased Corticomuscular Coherence in Idiopathic REM Sleep Behavior Disorder</article-title>. <source><italic toggle="yes">Front Neurol</italic></source>. <year>2012</year>;<volume>3</volume>:<fpage>60</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2012.00060</pub-id><pub-id pub-id-type="pmid">22536195</pub-id></mixed-citation>
      </ref>
      <ref id="cit0125">
        <label>125.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Choi</surname>
<given-names>GS</given-names></string-name>, <string-name><surname>Yun</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Hwang</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Can Corticomuscular Coherence Differentiate between REM Sleep Behavior Disorder with or without Parkinsonism?</article-title>
<source><italic toggle="yes">J Clin Med</italic></source>. <year>2021</year>;<volume>10</volume>(<issue>23</issue>):<fpage>5585</fpage>. doi:<pub-id pub-id-type="doi">10.3390/jcm10235585</pub-id><pub-id pub-id-type="pmid">34884285</pub-id></mixed-citation>
      </ref>
      <ref id="cit0126">
        <label>126.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Raggi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Manconi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Consonni</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Event-related potentials in idiopathic rapid eye movements sleep behaviour disorder</article-title>. <source><italic toggle="yes">Clin Neurophysiol</italic></source>. <year>2007</year>;<volume>118</volume>(<issue>3</issue>):<fpage>669</fpage>–<lpage>675</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clinph.2006.11.011</pub-id><pub-id pub-id-type="pmid">17208046</pub-id></mixed-citation>
      </ref>
      <ref id="cit0127">
        <label>127.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Raggi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lanza</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ferri</surname>
<given-names>RA</given-names></string-name>. <article-title>Review on P300 in Obsessive-Compulsive Disorder</article-title>. <source><italic toggle="yes">Front Psychiatry</italic></source>. <year>2021</year>;<volume>12</volume>:<fpage>751215</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fpsyt.2021.751215</pub-id><pub-id pub-id-type="pmid">34887786</pub-id></mixed-citation>
      </ref>
      <ref id="cit0128">
        <label>128.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Raggi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lanza</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ferri</surname>
<given-names>R</given-names></string-name>. <article-title>Auditory mismatch negativity in bipolar disorder: a focused review</article-title>. <source><italic toggle="yes">Rev Neurosci</italic></source>. <year>2022</year>;<volume>33</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1515/revneuro-2021-0010</pub-id><pub-id pub-id-type="pmid">33837681</pub-id></mixed-citation>
      </ref>
      <ref id="cit0129">
        <label>129.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gaudreault</surname>
<given-names>PO</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Abnormal occipital event-related potentials in Parkinson’s disease with concomitant REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Parkinsonism Relat Disord</italic></source>. <year>2013</year>;<volume>19</volume>(<issue>2</issue>):<fpage>212</fpage>–<lpage>217</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.parkreldis.2012.10.006</pub-id><pub-id pub-id-type="pmid">23107557</pub-id></mixed-citation>
      </ref>
      <ref id="cit0130">
        <label>130.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Santamaría</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rye</surname>
<given-names>DB</given-names></string-name>, et al. <article-title>Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2005</year>;<volume>65</volume>(<issue>2</issue>):<fpage>247</fpage>–<lpage>252</lpage>. doi:<pub-id pub-id-type="doi">10.1212/01.wnl.0000168864.97813.e0</pub-id><pub-id pub-id-type="pmid">16043794</pub-id></mixed-citation>
      </ref>
      <ref id="cit0131">
        <label>131.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Antelmi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Pizza</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Donadio</surname>
<given-names>V</given-names></string-name>, et al. <article-title>Biomarkers for REM sleep behavior disorder in idiopathic and narcoleptic patients</article-title>. <source><italic toggle="yes">Ann Clin Transl Neurol</italic></source>. <year>2019</year>;<volume>6</volume>(<issue>9</issue>):<fpage>1872</fpage>–<lpage>1876</lpage>. doi:<pub-id pub-id-type="doi">10.1002/acn3.50833</pub-id><pub-id pub-id-type="pmid">31386270</pub-id></mixed-citation>
      </ref>
      <ref id="cit0132">
        <label>132.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Berg</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Borghammer</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Fereshtehnejad</surname>
<given-names>SM</given-names></string-name>, et al. <article-title>Prodromal Parkinson disease subtypes - key to understanding heterogeneity</article-title>. <source><italic toggle="yes">Nat Rev Neurol</italic></source>. <year>2021</year>;<volume>17</volume>(<issue>6</issue>):<fpage>349</fpage>–<lpage>361</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41582-021-00486-9</pub-id><pub-id pub-id-type="pmid">33879872</pub-id></mixed-citation>
      </ref>
      <ref id="cit0133">
        <label>133.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gilat</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Marshall</surname>
<given-names>NS</given-names></string-name>, <string-name><surname>Testelmans</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Buyse</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Lewis</surname>
<given-names>SJG</given-names></string-name>. <article-title>A critical review of the pharmacological treatment of REM sleep behavior disorder in adults: time for more and larger randomized placebo-controlled trials</article-title>. <source><italic toggle="yes">J Neurol</italic></source>. <year>2022</year>;<volume>269</volume>(<issue>1</issue>):<fpage>125</fpage>–<lpage>148</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00415-020-10353-0</pub-id><pub-id pub-id-type="pmid">33410930</pub-id></mixed-citation>
      </ref>
      <ref id="cit0134">
        <label>134.</label>
        <mixed-citation publication-type="journal"><string-name><surname>de Almeida</surname>
<given-names>CMO</given-names></string-name>, <string-name><surname>Pachito</surname>
<given-names>DV</given-names></string-name>, <string-name><surname>Sobreira-Neto</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Tumas</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Eckeli</surname>
<given-names>AL</given-names></string-name>. <article-title>Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: a scoping review</article-title>. <source><italic toggle="yes">J Neurol Sci</italic></source>. <year>2018</year>;<volume>393</volume>:<fpage>63</fpage>–<lpage>68</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jns.2018.08.008</pub-id><pub-id pub-id-type="pmid">30118919</pub-id></mixed-citation>
      </ref>
      <ref id="cit0135">
        <label>135.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Li</surname>
<given-names>SX</given-names></string-name>, <string-name><surname>Lam</surname>
<given-names>SP</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, et al. <article-title>A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2016</year>;<volume>21</volume>:<fpage>114</fpage>–<lpage>120</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2015.12.020</pub-id><pub-id pub-id-type="pmid">27448481</pub-id></mixed-citation>
      </ref>
      <ref id="cit0136">
        <label>136.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ferri</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Marelli</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ferini-Strambi</surname>
<given-names>L</given-names></string-name>, et al. <article-title>An observational clinical and video-polysomnographic study of the effects of clonazepam in REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2013</year>;<volume>14</volume>(<issue>1</issue>):<fpage>24</fpage>–<lpage>29</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2012.09.009</pub-id><pub-id pub-id-type="pmid">23098778</pub-id></mixed-citation>
      </ref>
      <ref id="cit0137">
        <label>137.</label>
        <mixed-citation publication-type="journal"><string-name><surname>McCarter</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Boswell</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>St Louis</surname>
<given-names>EK</given-names></string-name>, et al. <article-title>Treatment outcomes in REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2013</year>;<volume>14</volume>(<issue>3</issue>):<fpage>237</fpage>–<lpage>242</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2012.09.018</pub-id><pub-id pub-id-type="pmid">23352028</pub-id></mixed-citation>
      </ref>
      <ref id="cit0138">
        <label>138.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kunz</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Bes</surname>
<given-names>F</given-names></string-name>. <article-title>Melatonin as a therapy in rem sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on rem-sleep regulation</article-title>. <source><italic toggle="yes">Mov Disorders</italic></source>. <year>1999</year>;<volume>14</volume>(<issue>3</issue>):<fpage>507</fpage>–<lpage>511</lpage>. doi:<pub-id pub-id-type="doi">10.1002/1531-8257(199905)14:3&lt;507</pub-id>::</mixed-citation>
      </ref>
      <ref id="cit0139">
        <label>139.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Boeve</surname>
<given-names>B</given-names></string-name>. <article-title>Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2003</year>;<volume>4</volume>(<issue>4</issue>):<fpage>281</fpage>–<lpage>284</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1389-9457(03)00072-8</pub-id><pub-id pub-id-type="pmid">14592300</pub-id></mixed-citation>
      </ref>
      <ref id="cit0140">
        <label>140.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Taximaimaiti</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Luo</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>XP</given-names></string-name>. <article-title>Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson’s Disease</article-title>. <source><italic toggle="yes">Curr Neuropharmacol</italic></source>. <year>2021</year>;<volume>19</volume>(<issue>12</issue>):<fpage>2233</fpage>–<lpage>2249</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1570159X19666210517115706</pub-id><pub-id pub-id-type="pmid">33998990</pub-id></mixed-citation>
      </ref>
      <ref id="cit0141">
        <label>141.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gilat</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Coeytaux jackson</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Marshall</surname>
<given-names>NS</given-names></string-name>, et al. <article-title>Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s disease: a Randomised Controlled Trial</article-title>. <source><italic toggle="yes">Mov Disorders</italic></source>. <year>2020</year>;<volume>35</volume>(<issue>2</issue>):<fpage>344</fpage>–<lpage>349</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.27886</pub-id></mixed-citation>
      </ref>
      <ref id="cit0142">
        <label>142.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kashihara</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Nomura</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Maeda</surname>
<given-names>T</given-names></string-name>, et al. <article-title>Beneficial Effects of Ramelteon on Rapid Eye Movement Sleep Behavior Disorder Associated with Parkinson’s Disease - Results of a Multicenter Open Trial</article-title>. <source><italic toggle="yes">Intern Med</italic></source>. <year>2016</year>;<volume>55</volume>(<issue>3</issue>):<fpage>231</fpage>–<lpage>236</lpage>. doi:<pub-id pub-id-type="doi">10.2169/internalmedicine.55.5464</pub-id><pub-id pub-id-type="pmid">26831015</pub-id></mixed-citation>
      </ref>
      <ref id="cit0143">
        <label>143.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Nomura</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kawase</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Watanabe</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Nakashima</surname>
<given-names>K</given-names></string-name>. <article-title>Use of ramelteon for the treatment of secondary REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Intern Med</italic></source>. <year>2013</year>;<volume>52</volume>(<issue>18</issue>):<fpage>2123</fpage>–<lpage>2126</lpage>. doi:<pub-id pub-id-type="doi">10.2169/internalmedicine.52.9179</pub-id><pub-id pub-id-type="pmid">24042525</pub-id></mixed-citation>
      </ref>
      <ref id="cit0144">
        <label>144.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dusek</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Busková</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Růzicka</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease</article-title>. <source><italic toggle="yes">Clin Neuropharmacol</italic></source>. <year>2010</year>;<volume>33</volume>(<issue>4</issue>):<fpage>186</fpage>–<lpage>190</lpage>. doi:<pub-id pub-id-type="doi">10.1097/WNF.0b013e3181e71166</pub-id><pub-id pub-id-type="pmid">20661025</pub-id></mixed-citation>
      </ref>
      <ref id="cit0145">
        <label>145.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Lan</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>Z</given-names></string-name>. <article-title>Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2016</year>;<volume>12</volume>(<issue>10</issue>):<fpage>1403</fpage>–<lpage>1409</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.6200</pub-id><pub-id pub-id-type="pmid">27568909</pub-id></mixed-citation>
      </ref>
      <ref id="cit0146">
        <label>146.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wilson</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Wurst</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Whatley</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Daniels</surname>
<given-names>RN</given-names></string-name>. <article-title>Classics in Chemical Neuroscience: pramipexole</article-title>. <source><italic toggle="yes">ACS Chem Neurosci</italic></source>. <year>2020</year>;<volume>11</volume>(<issue>17</issue>):<fpage>2506</fpage>–<lpage>2512</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acschemneuro.0c00332</pub-id><pub-id pub-id-type="pmid">32786316</pub-id></mixed-citation>
      </ref>
      <ref id="cit0147">
        <label>147.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Schmidt</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Koshal</surname>
<given-names>VB</given-names></string-name>, <string-name><surname>Schmidt</surname>
<given-names>HS</given-names></string-name>. <article-title>Use of pramipexole in REM sleep behavior disorder: results from a case series</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2006</year>;<volume>7</volume>(<issue>5</issue>):<fpage>418</fpage>–<lpage>423</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2006.03.018</pub-id><pub-id pub-id-type="pmid">16815751</pub-id></mixed-citation>
      </ref>
      <ref id="cit0148">
        <label>148.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kumru</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Carrasco</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2008</year>;<volume>31</volume>(<issue>10</issue>):<fpage>1418</fpage>–<lpage>1421</lpage>.<pub-id pub-id-type="pmid">18853939</pub-id></mixed-citation>
      </ref>
      <ref id="cit0149">
        <label>149.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Trenkwalder</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kies</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Rudzinska</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER)</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2011</year>;<volume>26</volume>(<issue>1</issue>):<fpage>90</fpage>–<lpage>99</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.23441</pub-id><pub-id pub-id-type="pmid">21322021</pub-id></mixed-citation>
      </ref>
      <ref id="cit0150">
        <label>150.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Di Giacopo</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Fasano</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Quaranta</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Della marca</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Bove</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Bentivoglio</surname>
<given-names>AR</given-names></string-name>. <article-title>Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2012</year>;<volume>27</volume>(<issue>4</issue>):<fpage>559</fpage>–<lpage>561</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.24909</pub-id><pub-id pub-id-type="pmid">22290743</pub-id></mixed-citation>
      </ref>
      <ref id="cit0151">
        <label>151.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Brunetti</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Losurdo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Testani</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Rivastigmine for refractory REM behavior disorder in mild cognitive impairment</article-title>. <source><italic toggle="yes">Curr Alzheimer Res</italic></source>. <year>2014</year>;<volume>11</volume>(<issue>3</issue>):<fpage>267</fpage>–<lpage>273</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1567205011666140302195648</pub-id><pub-id pub-id-type="pmid">24597506</pub-id></mixed-citation>
      </ref>
      <ref id="cit0152">
        <label>152.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ringman</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Simmons</surname>
<given-names>JH</given-names></string-name>. <article-title>Treatment of REM sleep behavior disorder with donepezil: a report of three cases</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2000</year>;<volume>55</volume>(<issue>6</issue>):<fpage>870</fpage>–<lpage>871</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.55.6.870</pub-id><pub-id pub-id-type="pmid">10994012</pub-id></mixed-citation>
      </ref>
      <ref id="cit0153">
        <label>153.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Larsson</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Aarsland</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ballard</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Minthon</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Londos</surname>
<given-names>E</given-names></string-name>. <article-title>The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson’s disease dementia</article-title>. <source><italic toggle="yes">Int J Geriatr Psychiatry</italic></source>. <year>2010</year>;<volume>25</volume>(<issue>10</issue>):<fpage>1030</fpage>–<lpage>1038</lpage>. doi:<pub-id pub-id-type="doi">10.1002/gps.2506</pub-id><pub-id pub-id-type="pmid">20872929</pub-id></mixed-citation>
      </ref>
      <ref id="cit0154">
        <label>154.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chagas</surname>
<given-names>MHN</given-names></string-name>, <string-name><surname>Eckeli</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Zuardi</surname>
<given-names>AW</given-names></string-name>, et al. <article-title>Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series</article-title>. <source><italic toggle="yes">J Clin Pharm Ther</italic></source>. <year>2014</year>;<volume>39</volume>(<issue>5</issue>):<fpage>564</fpage>–<lpage>566</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jcpt.12179</pub-id><pub-id pub-id-type="pmid">24845114</pub-id></mixed-citation>
      </ref>
      <ref id="cit0155">
        <label>155.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Anderson</surname>
<given-names>KN</given-names></string-name>, <string-name><surname>Shneerson</surname>
<given-names>JM</given-names></string-name>. <article-title>Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2009</year>;<volume>5</volume>(<issue>3</issue>):<fpage>235</fpage>–<lpage>239</lpage>.<pub-id pub-id-type="pmid">19960644</pub-id></mixed-citation>
      </ref>
      <ref id="cit0156">
        <label>156.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bamford</surname>
<given-names>CR</given-names></string-name>. <article-title>Carbamazepine in REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>1993</year>;<volume>16</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">8456232</pub-id></mixed-citation>
      </ref>
      <ref id="cit0157">
        <label>157.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Abenza Abildúa</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Miralles Martinez</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Arpa Gutiérrez</surname>
<given-names>FJ</given-names></string-name>, et al. <article-title>Conditions associated with REM sleep behaviour disorder: description of a hospital series</article-title>. <source><italic toggle="yes">Neurologia</italic></source>. <year>2019</year>;<volume>34</volume>(<issue>3</issue>):<fpage>159</fpage>–<lpage>164</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nrl.2016.11.011</pub-id><pub-id pub-id-type="pmid">28215911</pub-id></mixed-citation>
      </ref>
      <ref id="cit0158">
        <label>158.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Keir</surname>
<given-names>LHM</given-names></string-name>, <string-name><surname>Breen</surname>
<given-names>DP</given-names></string-name>. <article-title>New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson’s disease</article-title>. <source><italic toggle="yes">J Neurol</italic></source>. <year>2020</year>;<volume>267</volume>(<issue>1</issue>):<fpage>288</fpage>–<lpage>294</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00415-019-09651-z</pub-id><pub-id pub-id-type="pmid">31807917</pub-id></mixed-citation>
      </ref>
      <ref id="cit0159">
        <label>159.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Meloni</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Figorilli</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson’s disease</article-title>. <source><italic toggle="yes">Sleep Breath</italic></source>. <year>2022</year>;<volume>26</volume>(<issue>3</issue>):<fpage>1023</fpage>–<lpage>1031</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11325-021-02417-w</pub-id><pub-id pub-id-type="pmid">34403081</pub-id></mixed-citation>
      </ref>
      <ref id="cit0160">
        <label>160.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Shinno</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Kamei</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nakamura</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Inami</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Horiguchi</surname>
<given-names>J</given-names></string-name>. <article-title>Successful treatment with Yi-Gan San for rapid eye movement sleep behavior disorder</article-title>. <source><italic toggle="yes">Prog Neuropsychopharmacol Biol Psychiatry</italic></source>. <year>2008</year>;<volume>32</volume>(<issue>7</issue>):<fpage>1749</fpage>–<lpage>1751</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pnpbp.2008.06.015</pub-id><pub-id pub-id-type="pmid">18656519</pub-id></mixed-citation>
      </ref>
      <ref id="cit0161">
        <label>161.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kunz</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Stotz</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bes</surname>
<given-names>F</given-names></string-name>. <article-title>Treatment of isolated REM sleep behavior disorder using melatonin as a chronobiotic</article-title>. <source><italic toggle="yes">J Pineal Res</italic></source>. <year>2021</year>;<volume>71</volume>(<issue>2</issue>):<fpage>e12759</fpage>. doi:<pub-id pub-id-type="doi">10.1111/jpi.12759</pub-id><pub-id pub-id-type="pmid">34309908</pub-id></mixed-citation>
      </ref>
      <ref id="cit0162">
        <label>162.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Cammisuli</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Ceravolo</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Bonuccelli</surname>
<given-names>U</given-names></string-name>. <article-title>Non-pharmacological interventions for Parkinson’s disease mild cognitive impairment: future directions for research</article-title>. <source><italic toggle="yes">Neural Regen Res</italic></source>. <year>2020</year>;<volume>15</volume>(<issue>9</issue>):<fpage>1650</fpage>–<lpage>1651</lpage>. doi:<pub-id pub-id-type="doi">10.4103/1673-5374.276329</pub-id><pub-id pub-id-type="pmid">32209764</pub-id></mixed-citation>
      </ref>
      <ref id="cit0163">
        <label>163.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Cristini</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Weiss</surname>
<given-names>M</given-names></string-name>, <string-name><surname>De Las Heras</surname>
<given-names>B</given-names></string-name>, et al. <article-title>The effects of exercise on sleep quality in persons with Parkinson’s disease: a systematic review with meta-analysis</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2021</year>;<volume>55</volume>:<fpage>101384</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2020.101384</pub-id><pub-id pub-id-type="pmid">32987321</pub-id></mixed-citation>
      </ref>
      <ref id="cit0164">
        <label>164.</label>
        <mixed-citation publication-type="journal"><string-name><surname>McCarter</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Boeve</surname>
<given-names>BF</given-names></string-name>, <string-name><surname>Graff-Radford</surname>
<given-names>NR</given-names></string-name>, <string-name><surname>Silber</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>St Louis</surname>
<given-names>EK</given-names></string-name>. <article-title>Neuroprotection in idiopathic REM sleep behavior disorder: a role for exercise?</article-title>
<source><italic toggle="yes">Sleep</italic></source>. <year>2019</year>;<volume>42</volume>(<issue>6</issue>):<fpage>zsz064</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsz064</pub-id><pub-id pub-id-type="pmid">31184756</pub-id></mixed-citation>
      </ref>
      <ref id="cit0165">
        <label>165.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hughes</surname>
<given-names>KC</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Molsberry</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Valeri</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Schwarzschild</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Ascherio</surname>
<given-names>A</given-names></string-name>. <article-title>Physical activity and prodromal features of Parkinson disease</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2019</year>;<volume>93</volume>(<issue>23</issue>):<fpage>e2157</fpage>–<lpage>e2169</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000008567</pub-id><pub-id pub-id-type="pmid">31719136</pub-id></mixed-citation>
      </ref>
      <ref id="cit0166">
        <label>166.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Frazzitta</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Maestri</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ferrazzoli</surname>
<given-names>D</given-names></string-name>, et al. <article-title>Multidisciplinary intensive rehabilitation treatment improves sleep quality in Parkinson’s disease</article-title>. <source><italic toggle="yes">J Clin Mov Disord</italic></source>. <year>2015</year>;<volume>2</volume>:<fpage>11</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40734-015-0020-9</pub-id><pub-id pub-id-type="pmid">26788347</pub-id></mixed-citation>
      </ref>
      <ref id="cit0167">
        <label>167.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Memon</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Coleman</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Amara</surname>
<given-names>AW</given-names></string-name>. <article-title>Effects of exercise on sleep in neurodegenerative disease</article-title>. <source><italic toggle="yes">Neurobiol Dis</italic></source>. <year>2020</year>;<volume>140</volume>:<fpage>104859</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nbd.2020.104859</pub-id><pub-id pub-id-type="pmid">32243913</pub-id></mixed-citation>
      </ref>
      <ref id="cit0168">
        <label>168.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Howell</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Arneson</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Schenck</surname>
<given-names>CH</given-names></string-name>. <article-title>A novel therapy for REM sleep behavior disorder (RBD)</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2011</year>;<volume>7</volume>(<issue>6</issue>):<fpage>639</fpage>–<lpage>644A</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.1470</pub-id><pub-id pub-id-type="pmid">22171203</pub-id></mixed-citation>
      </ref>
      <ref id="cit0169">
        <label>169.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zuzuárregui</surname>
<given-names>JRP</given-names></string-name>, <string-name><surname>During</surname>
<given-names>EH</given-names></string-name>. <article-title>Sleep Issues in Parkinson’s Disease and Their Management</article-title>. <source><italic toggle="yes">Neurotherapeutics</italic></source>. <year>2020</year>;<volume>17</volume>(<issue>4</issue>):<fpage>1480</fpage>–<lpage>1494</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13311-020-00938-y</pub-id><pub-id pub-id-type="pmid">33029723</pub-id></mixed-citation>
      </ref>
      <ref id="cit0170">
        <label>170.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Pereira</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Muthusamy</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>De Pennington</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Joint</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Aziz</surname>
<given-names>TZ</given-names></string-name>. <article-title>Deep brain stimulation of the pedunculopontine nucleus in Parkinson’s disease. Preliminary experience at Oxford</article-title>. <source><italic toggle="yes">Br J Neurosurg</italic></source>. <year>2008</year>;<volume>22</volume>:<fpage>S41</fpage>–<lpage>44</lpage>. doi:<pub-id pub-id-type="doi">10.1080/02688690802448335</pub-id><pub-id pub-id-type="pmid">19085352</pub-id></mixed-citation>
      </ref>
      <ref id="cit0171">
        <label>171.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Stefani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lozano</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Peppe</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2007</year>;<volume>130</volume>(<issue>Pt 6</issue>):<fpage>1596</fpage>–<lpage>1607</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awl346</pub-id><pub-id pub-id-type="pmid">17251240</pub-id></mixed-citation>
      </ref>
      <ref id="cit0172">
        <label>172.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chambers</surname>
<given-names>NE</given-names></string-name>, <string-name><surname>Lanza</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Bishop</surname>
<given-names>C</given-names></string-name>. <article-title>Pedunculopontine Nucleus Degeneration Contributes to Both Motor and Non-Motor Symptoms of Parkinson’s Disease</article-title>. <source><italic toggle="yes">Front Pharmacol</italic></source>. <year>2019</year>;<volume>10</volume>:<fpage>1494</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2019.01494</pub-id><pub-id pub-id-type="pmid">32009944</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
